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Abstract
 Recent evidence suggests that leflunomide, a dihydroorotate dehydrogenase (DHODH) 
inhibitor, disrupts neural crest development and melanoma pathogenesis via inhibiting 
transcription elongation. DHODH is an enzyme in the pyrimidine biosynthetic pathway and 
inhibition of this enzyme by leflunomide triggers a low nucleotide state. Leflunomide effectively 
ablates the neural crest lineage in embryonic zebrafish, preventing the formation of mature 
melanocytes, among other neural crest lineages. This drug also effectively suppresses 
melanoma and is in a clinical trial, administered in combination with the BRAF inhibitor 
vemurafenib, for metastatic melanoma. Despite knowing that leflunomide targets transcription 
elongation, the mechanism by which low nucleotides directly regulates transcription is unknown.
 Here, we provide evidence that a transcriptional regulator, HEXIM1, is upregulated in 
response to leflunomide. HEXIM1 is assembled into the 7SK snRNP complex to sequester and 
inhibit the kinase P-TEFb. P-TEFb triggers elongation by phosphorylating RNA polymerase II 
and other pausing factors. Knockdown of hexim in zebrafish rescues the effects of leflunomide. 
HEXIM1 expression is low in human melanoma and overexpression of this gene can suppress 
melanoma onset in vivo in zebrafish. Increased HEXIM1 expression, in response to low 
nucleotides triggered by DHODH inhibition, sequesters P-TEFb away from genes associated 
iii
with melanoma pathogenesis, proliferation and cell cycle based on ChIP-seq and GRO-seq 
analyses. This inhibits productive transcription elongation at genes that maintain the tumorigenic 
state. Our study illustrates that HEXIM1 responds to cell stress to suppress tumorigenesis by 
inhibiting productive elongation of proliferative genes in melanoma. Targeting HEXIM1 can 
therefore prove useful in treating melanoma.
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Chapter 1:
Introduction
2Introduction
 Melanoma is a malignant form of skin cancer that is responsible for about 75% of skin 
cancer deaths (Schadendorf and Hauschild, 2014). Activating mutations in BRAF, NRAS and 
CKIT are found in 60-70% of cutaneous melanomas and these mutations result in an over-
activation of MAP kinase signaling that drives pathological cell proliferation (Schadendorf 
and Hauschild, 2014; Sullivan and Flaherty, 2013). Recently, there have been a number of 
advancements in anti-melanoma targeted therapeutics based on melanoma genetics. The FDA 
has recently approved two BRAF inhibitors and one MEK inhibitor to target the MAP kinase 
pathway, based on excellent patient responses in clinical trials (Eggermont et al., 2014). 
However, drug resistance is common and has limited the effectiveness of these targeted 
therapies (Schadendorf and Hauschild, 2014; Trunzer et al., 2013). There is a need to further 
investigate melanoma for other molecular mechanisms that can be exploited for therapeutic 
intervention.
Targeted Therapies for Melanoma
 Current targeted therapies have been limited to targeting the MAPK pathway 
(Schadendorf and Hauschild, 2014; Sullivan and Flaherty, 2013). This is both due to vigorous 
studies on mutations in RAS GTPases and RAF kinases as reviewed by Sullivan and Flaherty 
(Sullivan and Flaherty, 2013), as well as the ease of developing inhibitors to kinase members 
of the MAPK pathways (BRAF and MEK) that have well-defined enzymatic active sites. NRAS 
is mutated in 15-30% of melanoma and the predominant mutation prevents the enzyme from 
hydrolyzing GTP to GDP, thereby keeping RAS in an active conformation to constitutively 
activate BRAF and CRAF (Bardeesy et al., 2005; Jakob et al., 2012; Marquette et al., 2011). 
Other than being aberrantly activated by mutated NRAS, BRAF itself is also mutated in 40-60% 
of melanomas (Davies et al., 2002), with the most frequent mutation being the V600E amino 
3acid substitution in the kinase domain (Pollock et al., 2003). This mutation results in constitutive 
BRAF activation and initiates MEK phosphorylation (Beeram et al., 2005; Pollock et al., 2003). 
MEK consequently phosphorylates ERK, which in turn upregulates transcription in pro-growth 
and transformation genes (Beeram et al., 2005; Sullivan and Flaherty, 2013). In addition to 
being significantly mutated in melanoma, both BRAF and NRAS mutations are associated with 
poor prognosis for melanoma survival (Jakob et al., 2012; Long et al., 2011).
 Since the MAPK pathway features as an important signal transduction pathway in 
melanoma oncogenesis, there have been numerous efforts to design targeted therapies to 
members of the pathway. Selective BRAF inhibitors vemurafenib and dabrafenib have been 
developed and are currently approved for use in melanoma (Schadendorf and Hauschild, 
2014). Treatment of patient tumors containing the BRAFV600E mutation with either drug caused 
a reduction in phospho-ERK levels that correlates with significant clinical responses (Bollag et 
al., 2010; Joseph et al., 2010). A second type of MAPK pathway drug approved for melanoma 
is MEK inhibitor trametinib (Schadendorf and Hauschild, 2014). Although this drug shows more 
modest patient response compared to the aforementioned BRAF inhibitors (Ascierto et al., 
2012; Flaherty et al., 2012), it still provides an alternative means to target the MAPK pathway 
should tumors become resistant to BRAF inhibitors. Unfortunately, virtually all patients treated 
with these drugs will relapse, even after initial strong clinical responses, due to the MAPK 
pathway being reactivated by alternative means such as activation of RAS or upregulation 
of CRAF (Chapman et al., 2011; Sullivan and Flaherty, 2013). More work has to be done to 
discover novel pathways that can be therapeutically targeted in melanoma and hopefully, which 
will be more resistant to being bypassed by the tumor.
4Zebrafish as a Melanoma Model
 The zebrafish model has proved particularly useful for melanoma research. In a proof-of-
principle study, the role of human BRAF was examined via melanocyte-specific overexpression 
in zebrafish under the mitfa promoter (Patton et al., 2005). As mentioned previously, BRAFV600E 
is the most frequent mutation in human nevi and melanoma that makes this kinase constitutively 
active (Pollock et al., 2003). Since this mutation had not been functionally validated in vivo for 
its relevance in melanoma, Patton et. al. examined if zebrafish could be used as an appropriate 
model to study the effects of human BRAFV600E on melanoma. Interestingly, they demonstrate 
that overexpressing human mutated but not wild-type BRAF induced ectopic melanocyte 
patches (Patton et al., 2005). In addition, the overexpression of mutated BRAF in a p53-
deficient zebrafish line induced invasive melanoma (Patton et al., 2005). It must be emphasized 
that the human BRAF gene and not the zebrafish version of braf was examined, demonstrating 
that zebrafish and human melanoma biology are likely conserved. This study pioneered the 
use of zebrafish as an effective melanoma model, owing to its ability to recapitulate human 
phenotypes.
 Other than recapitulating human melanoma biology, zebrafish are advantageous as a 
cancer model over the more commonplace mouse model. Mice, being a mammalian system, 
are currently preferred for cancer research as they are closer to humans from an evolutionary 
standpoint. As a result, there have been a number of melanoma studies focused on transgenic 
mouse models as reviewed by Walker et. al. (Walker et al., 2011). However, the cost of 
generating and maintaining mouse strains is prohibitive to performing large-scale genetics 
experiments (White et al., 2013). As a result, mice have primarily been used to test a small 
number of candidate melanoma genes as well as potential melanoma therapeutics which have 
first been evaluated in cell culture systems (Walker et al., 2011). Zebrafish, on the other hand, 
can overcome these obstacles in mouse melanoma modeling. Compared to mice, zebrafish 
5are much cheaper to maintain and easier to handle. There is no risk of user injury caused by 
fish unlike bites received from mice, which can result in infection. In addition, zebrafish can be 
generated in large numbers, with each mating pair capable of laying up to 200-300 embryos 
(Tan and Zon, 2011). Since zebrafish embryos develop ex vivo, genetic manipulation such 
as gene knockdown or transgenesis is also straightforward, which is performed via injection 
of DNA or RNA into the one-cell stage embryo. Since mice develop in utero, the generation 
of transgenic lines requires genetic modification in mouse embryonic stem cells, followed by 
injection of cells into mouse blastocysts which are then transplanted into a pseudo pregnant 
female (Thomas and Capecchi, 1987). This gives zebrafish a huge advantage in terms of the 
ease and rate of transgenesis, and has enabled the use of zebrafish in genetic screens to probe 
melanoma biology (Ceol et al., 2011).
 The zebrafish have been particularly valuable in genetic screens for novel drivers of 
melanoma based on mutational data obtained from sequencing melanoma genomes (Ceol et 
al., 2011; White et al., 2013). Since current sequencing technologies have advanced to the 
point where melanoma genomes can be sequenced rapidly and cost-effectively, large volumes 
of mutational data have been obtained (Berger et al., 2012; White et al., 2013). There is 
a need to systematically test these newfound mutations in vivo in order to discover relevant 
mutations to oncogenesis. A genetic screen performed in zebrafish has demonstrated the 
potential of zebrafish to rapidly screen through candidate oncogenes to determine the ones 
that are relevant (Ceol et al., 2011). In this study, Ceol et. al. generate a zebrafish strain which 
is mitfa- and p53-deficient, and which also expresses the human BRAFV600E gene under the 
control of the mitfa promoter. They also generated a vector called MiniCoopR that contains 
an mitfa minigene and an mitfa promoter controlling expression of any candidate gene-of-
interest. The plasmid also contains Tol2 sites for Tol2 transposase-mediated transgenesis for 
efficient insertion into the fish genome. Using this system, they tested candidate human genes 
6from a region on chromosome 1 that was significantly amplified in human melanoma (Curtin 
et al., 2005) and identified SETDB1 amplification as a novel driver of melanoma. Results were 
statistically significant as a large number of fish could be easily generated for each candidate 
gene and analyzed for phenotypes. Such a study relies on the conservation of zebrafish and 
human biology, as well as the ease and cost-effectiveness of this system. This type of screening 
strategy would be unfeasible in mice. One can foresee future zebrafish-based screening studies 
that examine other mutated regions in melanoma to discover novel oncogenes and tumor 
suppressors.
 In addition to genetic screening, the zebrafish are highly amenable to chemical 
screening (Tan and Zon, 2011), as demonstrated by a recent melanoma study (White et al., 
2011). In this study, synchronized zebrafish embryos were screened with 2,000 chemicals to 
ascertain changes in neural crest marker crestin expression by in situ hybridization. This screen 
is possible owing to technology and low cost, that allows for the generation of large numbers of 
synchronized embryos for chemical treatment (Tan and Zon, 2011). A potent DHODH inhibitor, 
leflunomide that targets pyrimidine biosynthesis, was found to specifically downregulate crestin 
expression. The drug did not appear to be nonselectively toxic since the primary target of the 
drug appeared to be the neural crest lineage, as the rest of the embryo seemed morphologically 
intact. Interestingly, the drug could significantly debulk tumors in a melanoma mouse xenograft 
model and synergized with the FDA-approved BRAF inhibitor vemurafenib (Bollag et al., 2010) 
to suppress melanoma. A combination therapy of leflunomide and vemurafenib is currently 
in clinical trials for metastatic melanoma. This study demonstrates the feasibility of utilizing 
zebrafish to not only screen for novel melanoma therapeutics, but also assess in vivo toxicity at 
the same time.
 Based on current work, the zebrafish is a valuable model organism for studying 
melanoma. The advantages of low cost, ease of breeding and handling, ease of transgenesis 
7and amenability to screening make the zebrafish an attractive system to study melanoma with. 
In addition, the zebrafish can recapitulate human melanoma biology similar to the mouse model, 
without the inherent limitations of this mammalian model. The zebrafish will likely prove to be 
useful in filtering through the large amount of genetic data for melanoma for relevant oncogenes 
and tumor suppressors.
The Neural Crest and Melanoma
 Melanoma is a cancer of the melanocyte lineage, which are melanin pigment-producing 
cells residing in the epidermis. Melanin protects our skin from ultra violet radiation damage from 
the sun by attenuating this radiation (Kollias et al., 1991). Melanocytes are differentiated from 
the neural crest stem cells (NCSCs), which arise in the ectoderm at the margins of the neural 
tube in the developing embryo (Shakhova, 2014). The NCSCs are a transient and migratory 
cell population that gives rise to the melanocytes, among other lineages including smooth 
muscle cells, adipocytes, neurons, glial cells, chondrocytes and osteoblasts (Shakhova, 2014). 
Recent studies have shown that melanoma possesses neural crest-like characteristics (Boiko 
et al., 2010; Civenni et al., 2011; Schatton et al., 2008), suggesting that tumor cells could have 
undergone de-differentiation to acquire the migratory and self-renewal properties of the NCSCs. 
Not surprisingly, melanoma has been shown to possess similar genetic regulatory networks 
to NCSCs, being critically dependent on the transcription factor SOX10 for self-renewal and 
survival (Shakhova, 2014; Shakhova et al., 2012). SOX10 is regulated by NRAS (Shakhova, 
2014), which was mentioned previously as being commonly mutated in melanoma. Therefore, 
there is strong evidence that transcriptional regulation of differentiation plays an important role 
in melanoma malignancy, and more work has to be done to further understand this relationship.
8The Significance of Transcription Elongation in Differentiation
 Control of the elongation phase of RNA polymerase II (RNA Pol II) transcription plays a 
significant role in regulating gene expression in specific cell types and during differentiation as 
reviewed in Guo and Price (Guo and Price, 2013). A summary of the process is shown in Figure 
1.1. After initiation, RNA Pol II comes under the control of negative transcription elongation 
factors that include DSIF, NELF, Gdown1 and GNAF and becomes paused close to the 
promoter (Cheng et al., 2012a; Rahl et al., 2010). Release of these promoter proximal paused 
polymerases into productive elongation requires the kinase activity of the positive transcription 
elongation factor P-TEFb (Marshall et al., 1996). P-TEFb comprising cyclin-dependent kinase 9 
(Cdk9) and either cyclin T1 or T2 (CCNT1/CCNT2) in humans is able to phosphorylate RNA Pol 
II (Marshall et al., 1996), and phosphorylation of DSIF (Wada et al., 1998; Yamada et al., 2006) 
and NELF (Fujinaga et al., 2004) leads to the release of NELF from the elongation complex 
and the transition into productive elongation (Rahl et al., 2010). RNA Pol II elongation control is 
prevalent in metazoan species (Adelman and Lis, 2012). In many cell types over half of human 
(Rahl et al., 2010) and drosophila (Muse et al., 2007) genes are occupied by promoter proximal 
paused RNA Pol II and synthesis of essentially all mRNAs requires P-TEFb. 
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Figure 1.1 Regulation of Transcription Elongation
During the initiation step, RNA Pol II is recruited to the promoters of highly regulated genes and 
is held in a paused position by the binding of pausing factors such as NELF and DSIF. The arrival 
of P-TEFb, comprising CDK9 and either CCNT1 or CCNT2, is required to phosphorylate RNA Pol 
II at Ser-2 in the C terminal domain, DSIF and NELF. This causes dissociation of NELF, converts 
DSIF into a positive elongation factor, and shifts RNA Pol II into a state of productive elongation.
Transcriptional Regulation in the Neural Crest and Melanoma
 Transcriptional elongation has been shown to be an important regulator of neural crest 
differentiation and melanoma (Keegan et al., 2002; White et al., 2011). Zebrafish mutants in tran-
scription elongation factors spt5 and spt6 possess pigmentation defects possibly due to the ab-
sence of mature melanocytes (Keegan et al., 2002). Spt5 and spt6 promote transcription elonga-
tion and their loss seemingly inhibits productive elongation that hinders melanocyte differentiation 
(Keegan et al., 2002).
 In a related study, a chemical in situ hybridization screen for modulators of neural crest 
marker crestin expression discovered that a DHODH inhibitor called leflunomide (Kaplan, 2001) 
can ablate crestin expression and melanocytes in zebrafish embryos (White et al., 2011). DHODH 
is an enzyme in the nucleotide de novo biosynthesis pathway and its inhibition impairs pyrimidine 
nucleotide biosynthesis (Löffler et al., 1997). This inhibits elongation in key genes necessary for 
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melanoma tumorigenesis (White et al., 2011). The loss of melanocytes and pigmentation induced 
by leflunomide phenocopies the pigmentation defects in the spt5 and spt6 mutants (Keegan et al., 
2002; White et al., 2011). In addition, leflunomide synergizes with a hypomorphic allele of spt5 in 
zebrafish, causing complete ablation of the melanocytes at a sub-optimal dose in these mutants 
(White et al., 2011). The spt5 hypomorph experiences less severe transcriptional defects, so a 
low dose of leflunomide is sufficient to further inhibit elongation to similar effect as the spt5 null al-
leles (White et al., 2011). More importantly, leflunomide causes melanoma regression in a mouse 
xenograft model (White et al., 2011). These studies posit an important role for elongation in neural 
crest differentiation and melanoma. However, it is unclear how leflunomide directly pauses elon-
gation. It is possible that the action of leflunomide involves a negative regulator of elongation. 
HEXIM1, a Negative Regulator of Transcription Elongation
 One such factor that is known to negatively regulate elongation is HEXIM1, a component 
of the 7SK small nuclear ribonuclear protein (7SK snRNP), which might play a role in the effects 
of leflunomide. HEXIM1 has been shown to negatively regulate transcription in cell culture by se-
questering P-TEFb and inhibiting its kinase activity (Yik et al., 2003). Sequestering and inhibiting 
P-TEFb allows for regulation of transcriptional pause release, which in turn regulates differentia-
tion (Guo and Price, 2013; Zhou et al., 2012). HEXIM1 protein domains are highly conserved 
among humans, mice and zebrafish (Figure 1.2A). Phylogenetic analysis of HEXIM orthologues 
demonstrates that human and mouse HEXIM1 are closely related, while zebrafish hexim relates 
more closely with human and mouse HEXIM2 (Figure 1.2B). The HEXIM gene is also highly 
syntenic among humans, mice and zebrafish (Figure 1.2C). This suggests identical functioning of 
HEXIM in all three species.
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Human_HEXIM1      MAEPFLSEYQHQPQTSNCTGAAAVQEELNPERPPGAEERVPEEDSRWQSRAFPQLGGRPG 60
Mouse_Hexim1      MAEPLLTEHQHQPQTSNCTGAAVVHEEHTSERPPSAEERVPKEDSRWQSRASLQSGSRPG 60
Zf_hexim          --------------------MELIKEET-----------APEDDSRGRQRDYRTSVVSSK 29
Human_HEXIM2      -------------------MMATPNQTA-----------CNAESPVALEEAKTSGAPGSP 30
Mouse_Hexim2      --------------------MATVNHTN-----------CNTASPAALEEAKTSGGLRSP 29
                                          :.                 ..   ..        . 
Human_HEXIM1      PEGEGSLESQPPPLQTQACPESSCLREGEKGQNGDDSSAGGDFPPPAEVEPTPEAELLAQ 120
Mouse_Hexim1      QEGEGGLKHQLPPLQTNACPELSSLEKGEKGQNGEDLSTGG-ASPSAEGE--PMSESLVQ 117
Zf_hexim          QVQRNQFEICPGLVSGDVHPMCRDRSDPEP-RTGDAASDDG----------FPADKTSSK 78
Human_HEXIM2      QTPPERHDSGGSLPLTPRMESHSEDEDLAGAVGGLGWNSRS-------------PRTQSP 77
Mouse_Hexim2      QIAHEPHDFGGSQLLPSGQEIQSEDEGTVPAGDGSSCNIRG-------------SRTQSP 76
                         .                         *   .  .              .    
Human_HEXIM1      PCHDSEASKLGAPAAGGEEEWGQQQRQLGKKKHRRRPSKKKRHWKPYYKLTWEEKKKFDE 180
Mouse_Hexim1      PGHDSEATKQEAPAAGGEEPWGQQQRQLGKKKHRRRPSKKKRHWKPYYKLTWEEKKKFDE 177
Zf_hexim          --RDSECAAVNTDGVSD----GRQ----GKKKHRRRPSKKKRRWKPYFKLTWEEKKELDE 128
Human_HEXIM2      GGCSAEAVLA-------------------RKKHRRRPSKRKRHWRPYLELSWAEKQQRDE 118
Mouse_Hexim2      GGCSVEAVLA-------------------RKKHRRRPSKRKRHWRPYLELSWAEKQQRDE 117
                     . *.                      :*********:**:*:** :*:* **:: **
Human_HEXIM1      KQSLRASRIRAEMFAKGQPVAPYNTTQFLMDDHDQEEPDLKTGLYSKR-AAAKSDDTS-- 237
Mouse_Hexim1      KQSLRASRVRAEMFAKGQPVAPYNTTQFLMDDHDQEEPDLKTGLYPKR-AAAKSDDTS-- 234
Zf_hexim          RETARASRVRAEMFAKGLPVAPYNTTQFLMEEHDREEPDLNTELGGRKSGAIRSEDTASE 188
Human_HEXIM2      RQSQRASRVREEMFAKGQPVAPYNTTQFLMNDRDPEEPNLDVPHGISHPGSSGESEAG-- 176
Mouse_Hexim2      RQSQRASRVREEMFAKGQPLAPYNTTQFLMNDRDLEEPNLDVLHGPSHSGSGGENEAG-- 175
                  ::: ****:* ****** *:**********:::* ***:*..     : .:  ..::.  
Human_HEXIM1      DDDFMEEGGEED---GGSDGMGG---DGSEFLQRDFSETYERYHTESLQNMSKQELIKEY 291
Mouse_Hexim1      DEDFVEEAGEED---GGSDGMGG---DGSEFLQRDFSETYERYHAESLQNMSKQELIKEY 288
Zf_hexim          DENFEAEEDDEEEGGGGSDGMGRPGQAGGEFLQKDFSETYEKYHVEALQNMSKQELVREY 248
Human_HEXIM2      ----------------DSDGRGR---AHGEFQRKDFSETYERFHTESLQGRSKQELVRDY 217
Mouse_Hexim2      ----------------DSDGQGR---AHGEFQQRDFSEAYERYHTESLQGRSKQELVRDY 216
                                  .*** *      .** ::****:**::*.*:**. *****:::*
Human_HEXIM1      LELEKCLSRMEDENNRLR-----LESKRLGGDDARVRELELELDRLRAENLQLLTENELH 346
Mouse_Hexim1      LELEKCLSRKEDENNRLR-----LESKRLGGVDARVRELELELDRLRAENLQLLTENELH 343
Zf_hexim          LELEKCMSRLEEENNWLRHVRRNPESPADGTGSQRVRELEVEVEKLRAENNELLLKTPAS 308
Human_HEXIM2      LELEKRLSQAEEETRRLQ----QLQACTGQQSCRQVEELAAEVQRLRTENQRLRQENQMW 273
Mouse_Hexim2      LDLERRLSQAEQETRRLR----QLQGCSSRQPCQQVEELAAEVERLRTENQRLRQENEMW 272
                  *:**: :*: *:*.. *:      :.        :*.**  *:::**:** .*  :.   
Human_HEXIM1      RQQERAPLSK----FGD------------------------ 359
Mouse_Hexim1      RQQERAPLSK----FGD------------------------ 356
Zf_hexim          -NEPGLNQSQ----PS------------------------- 319
Human_HEXIM2      NREGCRCDEE----PGT------------------------ 286
Mouse_Hexim2      NREGGYCDQEKPASEGTPWPKVEAPFQTHTGQLGHREAGDR 313
NLS 
Identical -ve 
TBD 
A
HEXIM1 & HEXIM2: Identitites = 118/286 (41%), Positives = 150/286 (52%)
HEXIM1 & Hexim1: Identities = 308/356 (87%), Positives = 319/356 (90%)
HEXIM1 & Hexim2: Identities = 112/313 (36%), Positives = 137/313 (44%)
HEXIM1 & hexim: Identities = 126/319 (39%), Positives = 162/319 (51%)
HEXIM2 0.11104
Hexim2 0.11703
hexim 0.2496
HEXIM1 0.07238
Hexim1 0.06807
B
Human
Mouse
Zebrafish
C
acbd4
FMNL1
Fmnl1
ACBD4
Acbd4
PLCD3
Plcd3
HEXIM2HEXIM1
Hexim2Hexim1
hexim
Figure 1.2 HEXIM1 is Highly Homologous in Humans, Mice and Zebrafish
(A) Alignment of HEXIM orthologues in humans, mice and zebrafish using Clustal Omega. The 
conserved regions of the nuclear localization signal (NLS), identical region, negatively charged
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(Continued) region (-ve) and cyclin T binding domain (TBD) are highlighted. (B) HEXIM ortho-
logue phylogenetic tree by Clustal Omega. (C) HEXIM orthologue synteny analysis.
 A fraction of HEXIM1 is found a form of the 7SK snRNP that contains P-TEFb (Figure 1.3) 
(Michels and Bensaude, 2008; Nguyen et al., 2001; Yang et al., 2001; Yik et al., 2003). The 7SK 
snRNP consists of non-coding RNA, the 7SK snRNA, the 5’ methylphosphate capping protein 
MEPCE (also known as BCDIN3) and the 3’ end binding protein LARP7 (He et al., 2008; Jeronimo 
et al., 2007). Incorporation of dimeric HEXIM1 into the 7SK snRNP induces a conformational 
change in HEXIM1 that allows for P-TEFb binding (Barboric et al., 2005; Blazek et al., 2005; Li et 
al., 2005). The 7SK snRNP is also tightly regulated by calcium/calmodulin phosphatases (PP1α 
and PP2B), AKT, P300 and PKC (Chen et al., 2008; Cho et al., 2009; Contreras et al., 2007; Fu-
jinaga et al., 2012).
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Figure 1.3 Regulation of the 7SK snRNP
HEXIM, as part of the 7SK snRNP complex, sequesters and inhibits P-TEFb activity. Complex 
association and dissociation is modulated by a series of complex phosphorylation, dephosphory-
lation, acetylation and conformational change events.
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Tumor Suppressing Activity of HEXIM1
 In addition to being an essential regulatory component of gene expression, there is evi-
dence that the inability of the 7SK snRNP to function is relevant to cancer. HEXIM1, which is 
responsible for direct interaction with P-TEFb, is downregulated by estrogen to relieve negative 
regulation on genes involved in cell proliferation, possibly exacerbating breast cancer prolifera-
tion (Ogba et al., 2008; Wittmann et al., 2005). In prostate cancer, HEXIM1 modulates androgen 
receptor and TGF-β signaling (Mascareno et al., 2012). LARP7, the 3’ binding protein of the 7SK 
RNA, was found to be truncated and non-functional in gastric cancer (Cheng et al., 2012b). This 
truncation prevented the formation of the functional 7SK snRNP to suppress tumorigenic gene 
expression (Cheng et al., 2012b). Through a poorly understood feedback loop, any treatment 
or condition that inhibits the elongation by RNA Pol II causes release of P-TEFb from the 7SK 
snRNP and a subsequent increase in HEXIM1 gene expression (Guo and Price, 2013; Liu et 
al., 2014a). These treatments include a number of cancer drugs and investigational anti-cancer 
agents, suggesting a role for HEXIM1 in suppressing tumorigenesis.
 Since both leflunomide and HEXIM1 negatively regulate transcription elongation, we in-
vestigated if HEXIM1 is responsible for the effects of leflunomide on the neural crest and mela-
noma. Our genetic and biochemical studies demonstrate that HEXIM1 is required for lefluno-
mide-induced phenotypes through its sequestration of P-TEFb. HEXIM1 levels are modulated by 
nucleotide perturbations induced by leflunomide. Furthermore, HEXIM1 can suppress melanoma, 
independent of leflunomide, by modulating tumorigenic genes associated with melanoma. These 
results illustrate the importance of HEXIM1 induction as a stress response to nucleotide shortage. 
HEXIM1 induction inhibits transcription in cells, and consequently cell cycle and proliferation, until 
the stress is alleviated. This pathway can be targeted to suppress melanoma by initiating a non-
proliferative state in tumors.
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Introduction
 Control of the elongation phase of RNA polymerase II (RNA Pol II) transcription plays a 
significant role in regulating gene expression in specific cell types and during differentiation as 
reviewed in Guo and Price (Guo and Price, 2013). After initiation, RNA Pol II comes under the 
control of negative transcription elongation factors that include DSIF, NELF, Gdown1 and GNAF 
and becomes paused close to the promoter (Cheng et al., 2012a; Rahl et al., 2010). Release 
of these promoter proximal paused polymerases into productive elongation requires the kinase 
activity of the positive transcription elongation factor P-TEFb (Marshall et al., 1996). P-TEFb 
comprising cyclin-dependent kinase 9 (Cdk9) and either cyclin T1 or T2 (CCNT1/CCNT2) in 
humans is able to phosphorylate RNA Pol II (Marshall et al., 1996), and phosphorylation of DSIF 
(Wada et al., 1998; Yamada et al., 2006) and NELF (Fujinaga et al., 2004) leads to the release 
of NELF from the elongation complex and the transition into productive elongation (Rahl et al., 
2010). RNA Pol II elongation control is prevalent in metazoan species (Adelman and Lis, 2012). 
In many cell types over half of human (Rahl et al., 2010) and drosophila (Muse et al., 2007) genes 
are occupied by promoter proximal paused RNA Pol II and synthesis of essentially all mRNAs 
requires P-TEFb. 
 Transcriptional elongation has been shown to be an important regulator of neural crest 
differentiation and melanoma (Keegan et al., 2002; White et al., 2011). Zebrafish mutants in 
transcription elongation factors spt5 and spt6 possess pigmentation defects possibly due to 
the absence of mature melanocytes (Keegan et al., 2002). Spt5 and spt6 promote transcription 
elongation and their loss seemingly inhibits productive elongation that hinders melanocyte 
differentiation (Keegan et al., 2002). In a related study, a chemical in situ hybridization screen 
for modulators of neural crest marker crestin expression discovered that a dihydro-orotate 
dehydrogenase (DHODH) inhibitor called leflunomide (Kaplan, 2001) can ablate crestin expression 
and melanocytes in zebrafish embryos (White et al., 2011). DHODH is an enzyme in the nucleotide 
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de novo biosynthesis pathway and its inhibition impairs pyrimidine nucleotide biosynthesis (Löffler 
et al., 1997). This inhibits elongation in key genes necessary for melanoma tumorigenesis (White 
et al., 2011). The loss of melanocytes and pigmentation induced by leflunomide phenocopies the 
pigmentation defects in the spt5 and spt6 mutants (Keegan et al., 2002; White et al., 2011). In 
addition, leflunomide synergizes with a hypomorphic allele of spt5 in zebrafish, causing complete 
ablation of the melanocytes at a sub-optimal dose in these mutants (White et al., 2011). The 
spt5 hypomorph experiences less severe transcriptional defects, so a low dose of leflunomide is 
sufficient to further inhibit elongation to similar effect as the spt5 null alleles (White et al., 2011). 
More importantly, leflunomide causes melanoma regression in a mouse xenograft model (White 
et al., 2011). These studies posit an important role for elongation in neural crest differentiation and 
melanoma. However, it is unclear how leflunomide directly pauses elongation. It is possible that 
the action of leflunomide involves a negative regulator of elongation. One such factor that is known 
to negatively regulate elongation is HEXIM1, a component of the 7SK small nuclear ribonuclear 
protein (7SK snRNP) (Yik et al., 2003), which might play a role in the effects of leflunomide.
 HEXIM1 has been shown to negatively regulate transcription in cell culture by sequestering 
P-TEFb and inhibiting its kinase activity (Yik et al., 2003). Sequestering and inhibiting P-TEFb 
allows for regulation of transcriptional pause release, which in turn regulates differentiation (Guo 
and Price, 2013; Zhou et al., 2012). HEXIM1 protein domains are highly conserved among humans, 
mice and zebrafish. A fraction of HEXIM1 is found a form of the 7SK snRNP that contains P-TEFb 
(Michels and Bensaude, 2008; Nguyen et al., 2001; Yang et al., 2001; Yik et al., 2003). The 7SK 
snRNP consists of non-coding RNA, the 7SK snRNA, the 5’ methylphosphate capping protein 
MEPCE (also known as BCDIN3) and the 3’ end binding protein LARP7 (He et al., 2008; Jeronimo 
et al., 2007). Incorporation of dimeric HEXIM1 into the 7SK snRNP induces a conformational 
change in HEXIM1 that allows for P-TEFb binding (Barboric et al., 2005; Blazek et al., 2005; Li et 
al., 2005). The 7SK snRNP is also tightly regulated by calcium/calmodulin phosphatases (PP1α 
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and PP2B), AKT, P300 and PKC (Chen et al., 2008; Cho et al., 2009; Contreras et al., 2007; 
Fujinaga et al., 2012). 
 Since both leflunomide and HEXIM1 negatively regulate transcription elongation, we 
investigated if HEXIM1 is responsible for the effects of leflunomide on the neural crest and 
melanoma. Our genetic and biochemical studies demonstrate that HEXIM1 is required for 
leflunomide-induced phenotypes through its sequestration of P-TEFb. HEXIM1 levels are 
modulated by nucleotide perturbations induced by leflunomide. Furthermore, HEXIM1 can 
suppress melanoma, independent of leflunomide, by modulating tumorigenic genes associated 
with melanoma. These results illustrate the importance of HEXIM1 induction as a stress response 
to nucleotide shortage. HEXIM1 induction inhibits transcription in cells, and consequently cell 
cycle and proliferation, until the stress is alleviated. This pathway can be targeted to suppress 
melanoma by initiating a non-proliferative state in tumors.
Results
Knockdown of hexim and Other Protein Members of the 7SK snRNP Rescues Neural Crest 
Phenotypes Associated with DHODH Inhibition.
 Leflunomide is a potent DHODH inhibitor and treatment of developing zebrafish embryos 
with the drug ablates crestin and mitfa gene expression at 24 hours post fertilization (hpf) (White 
et al., 2011). Crestin is a zebrafish specific pan-neural crest marker (Luo et al., 2001) while mitfa 
is the master regulator of the melanocyte cell fate (Levy et al., 2006), indicating that leflunomide 
specifically represses these genes. In addition to the loss of gene expression, leflunomide also 
inhibits melanocyte differentiation from 24 to 48 hpf. The pausing of crestin and mitfa transcripts 
might be induced by the 7SK snRNP. 
 Morpholino knockdown of hexim rescues crestin and mitfa expression in leflunomide-
treated zebrafish embryos at 24 hpf (Figure 2.1A). Melanocytes are also rescued at 48 hpf (Figures 
2.1B and 2.1C). A hexim mismatch morpholino control did not rescue leflunomide phenotypes. 
Also, overexpressing human HEXIM1 via mRNA injection in conjunction with zebrafish hexim 
knockdown ablated the rescue. We validated hexim protein knockdown via western blot (Figure 
2.1D). In addition, knockdown of either larp7 or bcdin3, both members of the active 7SK snRNP 
together with hexim, also recapitulated the rescue of melanocytic gene expression and melanocytes 
(Figures 2.2A and 2.2B). These results suggest a role for the 7SK snRNP in maintaining RNA Pol 
II in its paused state in the neural crest lineage in response to DHODH inhibition, thereby leading 
to transcriptional pausing of neural crest and melanocytic genes. 
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Figure 2.1 Knockdown of hexim Rescues Leflunomide-associated Neural Crest Phenotypes
(A) Zebrafish embryos were injected with 8 ng of hexim or control morpholino (MO), as well 
as a combination of hexim MO and 300 pg of human HEXIM1 mRNA. Embryos were treated 
with either DMSO or 6.5 μM leflunomide at 50% epiboly and were subjected to in situ 
hybridization at 24 hpf for crestin and mitfa expression. Dorsal views of embryos are shown. 
(B) Embryos treated as described in (A) were also scored for melanocytes at 2 dpf. (C) Four 
separate clutches of embryos were analyzed for rescue of melanocytes under the conditions 
of uninjected, hexim MO injected, leflunomide treatment or hexim MO injected with leflunomide 
treatment. Percentages of the number of embryos rescued in each clutch are plotted. (D) 
Western blot for hexim and β-actin (actb) in uninjected and hexim MO injected embryos at 24 hpf.
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Figure 2.2 Knockdown of bcdin3 and larp7 Rescues Leflunomide-induced Phenotypes
(A) Zebrafish embryos were injected with 10 ng of bcdin3 or 12 ng of larp7 MOs that were 
previously published. Embryos were treated with either DMSO or 6.5 μM leflunomide at 50% 
epiboly and subjected to in situ hybridization at 24 hpf for crestin and mitfa expression. Dorsal 
views of embryos are shown. (B) Embryos treated as described in (A) were also scored for 
melanocytes at 2 dpf.
Hexim is Ubiquitously Expressed in Early Development.
 Leflunomide treatment primarily affects the neural crest lineage of developing zebrafish 
embryos. Hence, we first investigated if hexim is expressed in the neural crest and melanocytes 
in these embryos. We developed two anti-sense in situ hybridization (ISH) RNA probes targeting 
the 5’ or the 3’ end of the mature hexim transcript which were validated for specificity by sense 
control probes (Figures 2.3A and 2.3B). ISH was then performed on zebrafish embryos at different 
developmental stages. Hexim is ubiquitously expressed at early developmental stages (Figure 
2.3C) before 24 hpf. After 24 hpf, expression is observed mostly in the head. Ubiquitous hexim 
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expression is similarly observed in developing mouse embryos from E9.5 to E11.5 (Huang et al., 
2004; Montano et al., 2008). Hexim is therefore expressed in the neural crest lineage at early 
developmental stages, albeit non-specifically.
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Figure 2.3 Hexim is Ubiquitously Expressed in Developing Zebrafish Embryos
(A) Two 600bp in situ hybridization probes to the hexim mature transcript were designed. (B) 
Both antisense probes and their corresponding sense controls were tested on 18-somite stage 
zebrafish embryos. (C) Hexim expression at various zebrafish developmental stages with probe 
1. Results were identical for probe 2. 
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HEXIM is Upregulated in Zebrafish Embryos and Human Melanoma in Response to DHODH 
Inhibition.
 Since hexim seems to be responsible for leflunomide-induced phenotypes in the zebrafish, 
we investigated if leflunomide has an effect on HEXIM expression. We performed real time RT-
PCR on leflunomide-treated embryos and observed that hexim expression is upregulated by 2-fold 
(Figure 2.4A). In addition, hexim protein levels are upregulated by leflunomide (Figure 2.4C). 
Treatment of A375 human melanoma cells with A771726, the metabolized and functional form 
of leflunomide (Magne et al., 2006), also increases HEXIM1 mRNA and protein levels in a dose 
response manner (Figures 2.4B and 2.4D). Furthermore, we tested A771726 in our HEXIM1-
luciferase reporter system (Liu et al., 2014b), which we had previously shown to have an excellent 
response to HEXIM1 inducing drugs, in the A375 cells. As expected, A771726 significantly 
increased HEXIM1 expression over time, similar to our positive control HMBA that is known to 
upregulate HEXIM1 (Figure 2.4E). This indicates that both human HEXIM1 and zebrafish hexim 
respond to DHODH inhibition by increasing their mRNA and protein levels.
 Since we previously showed that drugs HMBA, SAHA and JQ1 can upregulate HEXIM1 
transcription via a transient release of P-TEFb from the 7SK snRNP that triggers elongation at the 
HEXIM1 locus (Bartholomeeusen et al., 2012; Contreras et al., 2007, 2009; Lenasi et al., 2008), 
we examined if leflunomide upregulates HEXIM1 by this mechanism as well. We performed 
glycerol gradient sedimentation experiments on A771726-treated A375 cell lysates at early time 
points and determined that P-TEFb component CCNT1 is indeed released from the 7SK snRNP 
fraction into the free P-TEFb fraction in the first 6 hrs of drug treatment (Figure 2.4F). At 24 hrs 
of drug treatment however, there was a decrease in the amount of CCNT1 in the free P-TEFb 
fraction (Figure 2.4F). Quantification of the ratio of the amount of CCNT1 protein in the free 
P-TEFb fraction over the 7SK snRNP-bound P-TEFb fraction reveals a linear increase in the ratio 
from 0 to 6 hrs, followed by a drop to the 0 hr level by 24 hrs (Figure 2.4G). This demonstrates an 
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initial increase in the amount of free P-TEFb versus bound P-TEFb, followed by a reincorporation 
of P-TEFb into the 7SK snRNP. To complement the glycerol gradient studies, we performed co-
immunoprecipitation for endogenous HEXIM1 in A375 cells treated with A771726 for 72 hrs and 
assessed the levels of the components of the 7SK snRNP that are co-bound. We detected not only 
more HEXIM1 in the A771726 treatment as expected, but also more LARP7, BCDIN3, CCNT1 
and CDK9 that are co-bound to HEXIM1 (Figure 2.4H). 
 Taken together, these experiments provide evidence that DHODH inhibition first causes 
an initial increase in HEXIM1 protein levels due to a transient release of P-TEFb from the 7SK 
snRNP, which can upregulate HEXIM1 transcription. In this way, leflunomide functions similarly to 
HMBA, SAHA and JQ1 by transiently releasing active P-TEFb from the 7SK snRNP to upregulate 
transcription elongation in HEXIM1, among other genes (Bartholomeeusen et al., 2012a; Contreras 
et al., 2007, 2009; Lenasi et al., 2008; Liu et al., 2014b). Increased HEXIM1 transcription and 
protein synthesis following the initial release of P-TEFb from the 7SK snRNP means there is now 
more new HEXIM1 to consequently sequester and inactivate P-TEFb, inhibiting the transition 
from a transcriptional pause to productive elongation (Bartholomeeusen et al., 2012; Contreras et 
al., 2007, 2009).
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Figure 2.4 DHODH Inhibition Upregulates HEXIM to Sequester P-TEFb
(A) Real time RT-PCR on 24 hpf zebrafish embryos treated with leflunomide to examine hexim 
expression, normalized to gapdh. (B) Real time RT-PCR on A375 cells treated with A771726 for 
72 hrs to examine HEXIM1 expression, normalized to GAPDH. (C) Western blot for hexim on 24 
hpf zebrafish embryos treated with leflunomide from 50% epiboly to 24 hpf. (D) Western blot for 
HEXIM1 on A375 cells treated with A771726 for 72 hrs. (E) HEXIM1-luciferase reporter assay 
in A375 cells treated with DMSO or 25 μM A771726 and monitored over time. 10 mM HMBA 
treatment at 24 hrs, which is known to induce HEXIM1 expression, was the positive control.
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(Continued) (F) Cell lysates of A375 cells treated with 50 μM A771726 at various time points 
were subjected to 10-30% glycerol gradient sedimentation. CCNT1 in fractions containing free 
P-TEFb and 7SK snRNP-bound P-TEFb was detected by western blotting. (G) Quantification 
of the ratio of the amount of CCNT1 protein in the free P-TEFb fraction versus the 7SK snRNP-
bound P-TEFb fraction based on western band intensities in (F). (H) Co-immunoprecipitation of 
HEXIM1 was performed on A375 cells treated with DMSO or 60 μM A771726 for 72 hrs. Input, 
IgG and HEXIM1 IP samples were analyzed by western blotting for 7SK snRNP members and 
β-Actin (ACTB).
HEXIM1 Expression is Low in Melanoma.
 As leflunomide causes a proliferation defect in the A375 human melanoma line that 
correlates with increased HEXIM1 mRNA and protein levels, we looked for evidence of alterations in 
HEXIM1 expression in human melanoma. We analyzed two existing human melanoma microarray 
datasets for HEXIM1 expression (Lin et al., 2008; Talantov et al., 2005). The Talantov et al. study 
examines gene expression from primary melanoma and benign skin nevi tissues, while the Lin 
et al. study examines gene expression in melanoma short-term cultures and cell lines. We found 
that HEXIM1 is significantly downregulated by at least 2-fold in 78% of human nevi compared to 
normal skin controls (Figures 2.5A and 2.6A). When comparing human melanoma and skin, 100% 
of melanoma cases are downregulated by at least 2-fold (Figures 2.5A and 2.6A). Considering 
short-term cultures and cell lines versus normal melanocyte lines, 44% of melanoma cases have 
HEXIM1 downregulated by at least 2-fold (Figures 2.5B and 2.6A). Hence by expression, HEXIM1 
levels seem to be downregulated in melanoma. 
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Figure 2.5 HEXIM1 is Downregulated in Human Melanoma
(A) Gene expression plot of HEXIM1 microarray data from the Talantov et al. melanoma study 
showing fold change of nevi/tumor samples versus normal skin controls, which are set to 
1-fold. (B) Gene expression plot of HEXIM1 microarray data from the Lin et al. melanoma study 
(Continued) showing fold change of primary melanoma cultures, melanoma cell lines and a 
breast cancer cell line versus melanocyte culture controls, which are set to 1-fold. (C) Bar graph 
summarizing overall H-scores for normal epidermis, nevi and melanoma samples.
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 In addition to gene expression analyses, we performed immunohistochemistry for HEXIM1 
on human melanoma tissue microarrays and scored them by the H-score method (McClelland et 
al., 1990). Remarkably, 66% of nevi and 72% of human melanoma samples showed low H-scores 
of < 100, which corresponds to low HEXIM1 protein levels (Figures 2.5C and 2.6B). 6% of nevi 
and 13% of melanoma showed high HEXIM1 levels with H-scores of > 200 (Figures 2.6B and 
2.6D). 100% of normal epidermal samples scored high for HEXIM1 expression, with 94% of 
samples possessing H-scores of > 200 (Figures 2.6B and 2.6D). Since melanoma is derived from 
melanocytes, we examined normal epidermal sections co-stained for HEXIM1 and MART1, a 
melanocyte specific cell surface antigen (Coulie et al., 1994; Kawakami et al., 1994). As expected, 
melanocytes expressing high levels of MART1 also express high levels of HEXIM1, meaning that 
HEXIM1 protein is high in normal melanocytes compared to nevi and melanoma (Figure 2.6C). 
These results mirror both our analyses of HEXIM1 expression in the Talantov et. al. and Lin et. 
al. studies. The aforementioned mRNA and protein analyses therefore suggest that HEXIM1 can 
functionally suppress tumors, and is therefore downregulated in melanoma.
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Gene Comparison P-value1 P-value2 Reference
HEXIM1 Talantov et al.78% <0.05 -3.53 <0.05
100% <0.05 -18.6 <0.05
Lin et al.44% <0.05 -1.69 0.0854
1P-value of comparison between samples > 2-fold downregulated vs. controls.
2P-value of mean fold change of all samples vs. controls.
% of samples > 2-fold
downregulated
Nevi vs. normal skin
Melanoma vs. normal skin
Melanoma vs. melanocyte
cultures
Mean fold
change
A
B
Sample Type H-score No. of Samples % of Samples
0 0 0
1 - 100 0 0
101 - 200 1 6
201 - 300 16 94
0 4 22
1 - 100 8 44
101 - 200 5 28
201 - 300 1 6
0 8 10
1 - 100 51 62
101 - 200 12 15
201 - 300 11 13
Epidermis 
(n=17)
Nevi
(n=18)
Melanoma 
(n=82)
D
IgG
HEXIM1
Epidermis
Nevus
(HEXIM1 Low)
Melanoma
(HEXIM1 Low)
Nevus
(HEXIM1 High)
Melanoma
(HEXIM1 High)
C
HEXIM1
+
MART1
Epidermis
Figure 2.6 HEXIM1 mRNA and Protein Levels are Downregulated in Melanoma
(A) Microarray HEXIM1 data from the Talantov et al. and Lin et al. studies are presented in 
two ways. Firstly, the percentage of nevi/melanoma samples with HEXIM1 expression more 
than 2-fold downregulated versus the average expression level of the controls is tabulated. The 
associated p-value is calculated by comparing only samples with more than 2-fold downregulation 
with control samples using Student’s two-tailed t-test. Secondly, the mean fold change of all nevi/
melanoma samples versus controls is tabulated with its associated p-value. (B) Tabulation of 
H-scores from a human melanoma tissue microarray immuno-stained for HEXIM1 protein. A lower 
H-score corresponds to lower HEXIM1 protein levels. (C) Immunohistochemical co-staining of 
HEXIM1 (blue) and MART1 (brown) in a normal human epidermis section at 400x magnification. 
The white arrow indicates a normal melanocyte that is positively co-stained by both HEXIM1 
and MART1. (D) Immunohistochemical staining of HEXIM1 (pink) in normal epidermis, nevi and
(Continued) melanoma samples with low (H-score < 100) or high (H-score > 100) HEXIM1 levels 
from a human tissue microarray at 400x magnification.
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HEXIM Overexpression Suppresses Melanoma Onset in vivo.
 Decreased HEXIM1 expression in human melanoma suggests that HEXIM1 can suppress 
tumorigenesis and  is consequently downregulated in tumors so they can gain a competitive growth 
advantage. To investigate the in vivo action of HEXIM on melanoma directly, we overexpressed 
human HEXIM1 and zebrafish hexim in the MiniCoopR zebrafish melanoma assay system (Ceol 
et al., 2011). This system allows for melanocyte-specific expression of genes-of-interest, and 
enables the tracking of tumorigenesis over time. Compared to the EGFP background control and 
the SETDB1 positive control, which accelerates tumor onset, both human HEXIM1 and fish hexim 
effectively suppress melanoma onset (Figures 2.7A and 2.7B). 80% of HEXIM1/hexim fish remain 
tumor-free at the 25-week endpoint, while only 30% of EGFP fish and 10% of SETDB1 fish are 
tumor-free. HEXIM1 can therefore robustly suppress melanoma in our zebrafish in vivo system.
 We next investigated if HEXIM1 suppression of tumorigenesis is dependent on its P-TEFb 
sequestration function. It has been shown that the HEXIM1/P-TEFb interaction is modulated by 
mutating HEXIM1 amino acid residues at S268, T270, T276 and S278, located at the P-TEFb 
binding domain (Contreras et al., 2007). Mutating these sites to aspartate generates HEXIM1-
4D, which ablates P-TEFb binding and renders HEXIM1 non-functional for inhibiting transcription 
elongation. Conversely, mutating these sites to alanine generates HEXIM1-4A, which can 
efficiently sequester P-TEFb. Overexpressing HEXIM1-4A suppresses tumors to a similar extent 
as HEXIM1 and hexim (Figure 2.7C). Conversely, overexpressing HEXIM1-4D did not suppress 
tumors and tumorigenesis continued at the background rate similar to EGFP (Figure 2.7C).
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Figure 2.7 HEXIM Overexpression Suppresses Melanoma
(A) 19 week old Tg(mitfa:BRAFV600E);p53-/-;mitfa-/- zebrafish with rescued melanocytes expressing 
tumor accelerator SETDB1, background control EGFP or HEXIM1/hexim in the MiniCoopR 
system. (B) Tumor-free survival curves were generated for MiniCoopR zebrafish over a 25-week 
time period. Percentages of the total numbers of zebrafish that were tumor-free each week are 
plotted. We tested both human HEXIM1 and zebrafish hexim overexpression in this system. The 
positive and background controls are known tumor accelerator SETDB1 and EGFP respectively. 
(C) Tumor-free survival curves were also generated for overexpression of human HEXIM1-4A, 
which can efficiently bind P-TEFb, and human HEXIM1-4D, which does not bind P-TEFb, in this 
system.
 To validate MiniCoopR integration and expression of the appropriate transgenes in our 
fish, we genotyped transgenic fish from tail fin clips containing melanocytes. We used PCR 
primers specific for human HEXIM1 to amplify a 212 bp region containing the HEXIM1-4A and 
-4D mutations (Figure 2.8A). The PCR yielded products only for fish containing human HEXIM1 
constructs and not for those containing EGFP or zebrafish hexim (Figure 2.8A). The products 
were then sequenced to confirm that fish of each strain had the appropriate HEXIM1 construct 
integrated (Figure 2.8B). We also performed HEXIM1 western blots on representative tumor and 
skin samples harvested from fish of each genotype to ensure that construct integration resulted 
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in the production of functional protein (Figure 2.8C). As expected, skin and tumor samples from 
SETDB1 and EGFP transgenic fish did not express human HEXIM1 protein while all HEXIM1 
transgenic fish expressed significant levels of human HEXIM1 protein (Figure 2.8C). We did 
not detect any appreciable zebrafish hexim protein in the adult MiniCoopR fish skin and tumor 
samples, unlike in the 24 hpf embryo, where hexim protein is highly expressed. Zebrafish hexim 
is detected at the ~45 kD mark unlike human HEXIM1, which is larger and is detected at ~60 kD. 
 In addition to the effects in adult zebrafish, we also investigated the effects of HEXIM1 
overexpression in melanocytes during development. To this end, we generated stable lines from 
transient fish that were validated for MiniCoopR integration and HEXIM1 protein expression as 
mentioned previously (Figures 2.8A, 2.8B and 2.8C). Validated HEXIM1, HEXIM1-4A and -4D 
MiniCoopR transgenic fish were outcrossed to the Tg(mitfa:BRAFV600E);p53-/-;mitfa-/- strain to 
generate the stable lines. We outcrossed these stables to the Tg(mitfa:BRAFV600E);p53-/-;mitfa-/- 
strain and examined the melanocytes at 2 dpf, using a Tu wildtype strain incross as control (Figure 
2.8D). These outcrosses produced offspring with an embryonic decrease in melanocytes similar 
to the effects of leflunomide, in the case of HEXIM1 and HEXIM1-4A, but not EGFP or HEXIM1-
4D, which maintain melanocytes comparable to the wildtype Tu strain. This is only a partial 
phenocopy of leflunomide since crestin expression is unchanged (data not shown). HEXIM1 is 
being specifically overexpressed in melanocytes under the control of the mitfa promoter, so the 
early neural crest cells affected by leflunomide are still present in the transgenic embryos.
 With transient and stable expression of HEXIM1 and its mutated forms in zebrafish 
melanocytes, we provide in vivo evidence for the tumor suppressing function of HEXIM 
independent of leflunomide, and show that the ability of HEXIM to sequester P-TEFb is required 
for this function.
33
A
MCR
HEXIM1
MCR
HEXIM1-4A
MCR
HEXIM1-4D
S TE T SE
A AE A AE
D DE D DE
C
B
MCR EGFP MCR hexim MCR HEXIM1
MCR
HEXIM1-4A
HEXIM1
plasmid
+ve
cntr
MCR
HEXIM1-4D
HEXIM1
plasmid
no PCR
cntr
No DNA
-ve
cntr
HEXIM1
ACTB
HEXIM1
Skin
EGFP
Skin/Tumors
SETDB1
Skin/Tumors
HEXIM1-4A
Skin
HEXIM1-4D
Skin/Tumors
100/100
9/20
MCR EGFP
Tu (Wildtype)
57/95
52/89
88/108
MCR HEXIM1
MCR HEXIM1-4A
MCR HEXIM1-4D
2 dpf embryosD
Figure 2.8 Validation of MiniCoopR HEXIM1 Integration and Overexpression in Adult 
Tg(mitfa:BRAFV600E);p53-/-;mitfa-/- Zebrafish, and Examination of Embryonic Phenotypes in 
Transgenic Zebrafish
(A) MiniCoopR transient and stable lines were validated by extracting genomic DNA from tail fin 
clips of adult zebrafish. The region of human HEXIM1 that was mutated was then amplified by 
PCR. PCR was run on fin clips from MCR EGFP fish, MCR hexim fish, a HEXIM1 plasmid, a no-
DNA control and HEXIM1 plasmid with no-PCR for comparison. (B) PCR amplification products
(Continued) from (A) were sequenced to confirm strains containing WT HEXIM1, HEXIM-4A or 
-4D. A representative sequencing trace shows that amino acids S268, T270, T276 and S278 in 
human HEXIM1 were mutated to alanine in HEXIM1-4A and aspartate in HEXIM1-4D. (C) Three 
representative adult MiniCoopR-integrated zebrafish for each strain were sacked and protein was 
isolated from their skin or tumors, if present. Western blots for HEXIM1 and β-Actin were then per-
formed on these samples. (D) Side and dorsal views of 2 dpf zebrafish embryos produced from 
incrosses of the Tu wildtype strain and outcrosses of MiniCoopR transgenic stable lines of EGFP, 
HEXIM1, HEXIM1-4A and HEXIM1-4D with the Tg(mitfa:BRAFV600E);p53-/-;mitfa-/- strain.
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Induction of HEXIM1 by Leflunomide Reduces Productive Elongation.
 Since HEXIM1 upregulation by leflunomide is sufficient to suppress tumors by sequestering 
P-TEFb, we investigated the transcriptional mechanism of how leflunomide-induced HEXIM1 can 
suppress tumorigenesis. We first performed Global Run-On sequencing (GRO-seq) on A375 cells 
treated with leflunomide or A771726 for 48 hrs to confirm the pausing phenotype observed by 
RNA Pol II ChIP-seq in our previous study. Only gene loci that were considered expressed in 
the DMSO condition were used in the GRO-seq analysis for DMSO, leflunomide and A771726 
conditions. These genes are shortlisted based on a traveling ratio (TR) cutoff of less than 7.5 in 
the DMSO condition, similar to our previous study (White et al., 2011). TR is a measure of RNA 
Pol II transcription along a gene in which read density at the promoter is divided by read density 
along the gene body (Rahl et al., 2010). A higher TR corresponds to an increase in transcriptional 
pausing. Based on mapped reads, RNA Pol II occupancy at the promoters and gene bodies is 
plotted for the short-listed gene loci in all three conditions (Figure 2.9A). The overall traveling 
ratios obtained from Figure 2.9A demonstrate a significant increase in TR for both leflunomide 
and A771726 treatment (Figure 2.9B). Gene meta-analysis also shows that RNA Pol II density is 
significantly lower in the gene body with DHODH inhibition (Figure 2.9C). Example tracks of genes 
unaffected and affected by drug are shown in Figure 2.9D. An unaffected gene is housekeeping 
gene β-Actin (ACTB), while an affected gene is melanoma-associated transcription factor HMGA2 
(Raskin et al., 2013). The GRO-seq data supports the hypothesis that DHODH inhibition induces 
a transcriptional pause in these melanoma cells. 
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Figure 2.9 DHODH Inhibition Induces a Transcriptional Pause on Tumorigenic Genes
(A) GRO-seq read densities at the promoter (P) or within the Gene Body (GB) of genes with RNA 
Pol II traveling ratio (TR) < 7.5 from A375 human melanoma cells after 48 hr treatment with DMSO 
(white), 25 μM leflunomide (blue) or 25 μM A771762 (red) (mean of two replicates). (B) TR plots 
of genes from the GRO-seq experiment described in (A). (C) Metagene analysis of RNA Pol II 
occupancy +/-2 kb around transcription units from GRO-seq described in (A). (D) Representative 
traces of genes unaffected (ACTB) or affected (HMGA2) by leflunomide and A771726 treatment.
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 GRO-seq illustrates that DHODH inhibition is responsible for inducing a transcriptional 
pause, but does not provide any evidence for the involvement of HEXIM1. We therefore examined 
Ser-2 phosphorylation at the C-terminal domain (CTD) of RNA Pol II in A375 cells treated with 
A771726 in conjunction with HEXIM1 siRNA knockdown. The transition into productive elongation 
mediated by P-TEFb leads to increased Ser-2 phosphorylation in the CTD of the large subunit of 
RNA Pol II (Peng et al., 1998; Wei et al., 1998; Yang et al., 2001; Zhu et al., 1997). In cells with 
control siRNA, Ser-2 phosphorylation is decreased with a 48 hr drug treatment, along with a con-
comitant increase in HEXIM1 levels (Figure 2.10A). We expect this decrease in Ser-2 phosphory-
lation since the GRO-seq data shows there is a significant reduction in productive elongation at 
actively transcribed gene loci. This decrease in Ser-2 phosphorylation can be rescued by HEXIM1 
knockdown (Figure 2.10A). DHODH inhibition also causes a previously undefined transcription 
initiation defect, evident from the decrease in Ser-5 phosphorylation caused by A771726 (Figure 
2.10A). This is only partially rescued by HEXIM1 knockdown. These results provide support for 
a model that DHODH inhibition results in HEXIM1 induction and reduction of RNA Pol II Ser-2 
phosphorylation.
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Figure 2.10 HEXIM1 Induction by Leflunomide Causes Transcriptional Pausing in Genes 
Associated with Cell Proliferation and Survival
(A) Western blot on A375 cells treated with 60 μM A771726 for 48 hrs combined with siRNA 
knockdown for HEXIM1. Proteins detected are RNA Pol II C-terminal domain Ser-2 and Ser-
5 phosphorylation, total RNA Pol II and HEXIM1. (B) Venn diagram of the overlap of genes 
which transcripts have a RNA Pol II TR fold change > 1.3 in the leflunomide (blue) or A771762 
(red) treated condition. (C) Ingenuity pathway analysis on the 2,003 overlapping genes from 
leflunomide and A771726 GRO-seq in (B) that are paused. (D) Venn diagram of the overlap of
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(Continued) genes from (B) and the list of paused genes from our previously published RNA Pol II 
ChIP-seq data on A375 cells treated with leflunomide (White et al., 2011). (E) Ingenuity pathway 
analysis on the 137 overlapping genes among the data sets in (D). (F) Table of transcription factor 
motifs that are significantly enriched in genes paused by DHODH inhibition but not in unpaused 
genes. Motifs were shortlisted based on an enrichment p-value < 1.0E-04 in the paused gene list 
but not in the unpaused list.
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 To examine the genetic mechanism of how DHODH induced transcriptional pausing 
suppresses melanoma, we obtained a list of 2,003 overlapping significantly paused genes (fold 
change in TR > 1.3 drug versus DMSO) from the GRO-seq experiment to analyze in Ingenuity 
Pathway Analysis (Figure 2.10B). Genes involved in gene expression, cell proliferation, and cell 
death and survival are significantly enriched (Figure 2.10C). Also, we examined the overlap of the 
GRO-seq data with our previously published ChIP-seq paused gene list and analyzed this list of 
137 genes via Ingenuity Pathway Analysis (Figure 2.10D). This gene list also showed enrichment 
in cell cycle and proliferation pathways, similar to the pathways enriched by examining only GRO-
seq data (Figure 2.10E). In addition, we generated a list of 368 neural crest associated genes 
(Table 2.1) by gene expression and gene ontology analyses utilizing the zebrafish whole-mount 
mRNA expression database (http://zfin.org/cgi-bin/webdriver?MIval=aa-xpatselect.apg) and 
the gene ontology database AmiGO (Carbon et al., 2009) (http://amigo.geneontology.org). We 
compared this list to our GRO-seq paused gene list from Figure 2.10B and found that 33 neural 
crest associated genes are significantly paused in the GRO-seq experiment (Table 2.2). Of these 
genes, 5 are known to exacerbate melanoma. GDNF, SMARCA4 and STMN1 are upregulated 
in melanoma and contribute to melanoma pathogenesis (Chen et al., 2013; Lin et al., 2010; 
Ohshima et al., 2010). CCDN1 is frequently mutated in melanoma and contributes to melanoma 
progression (Sauter et al., 2002). Elevation of CTSB contributes to the metastatic potential of 
melanoma (Sloane et al., 1982). Thus, DHODH inhibition seems to target melanoma by reducing 
productive elongation at genes associated with melanoma progression and metastasis, as well as 
general cell cycle and proliferation genes, negating their tumorigenic effect.
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Table 2.1 List of Neural Crest-Associated Genes
ABCC4 CHD7 EDNRA GBX2 L1CAM OVOL1 RADIL SOX9 ZEB2
ACBD7 CHGA EDNRB GCH1 LAMA5 OVOL2 RALDH2 SPRY1 ZFP36L1
ACVR1 CHPF EFNB1 GDF6 LATS2 PAH RARA SQSTM1 ZIC1
ACVR2A CHSY3 EFNB2 GDNF LEF1 PAICS RARG STAT3 ZIC2
ACVR2B CITED2 EGR2 GIPC2 LEO1 PARP3 RASL11A STMN1 ZIC3
AFAP1L1 CITED4 EIF2S1 GMPS LHX6 PAX3 RAX STX7 ZIC4
AK4 CNBP ERBB2 GPD1 LIMD1 PAX7 RBP4 SUMO1 ZIC5
ALCAM CNDP2 ERBB3 GPR143 LMO4 PAX9 RDH10 SUMO2 ZMAT1
ALDH16A1 CNN3 ERBB4 GREM1 LRAT PBX1 RET SUMO3
ALDH1A2 COL11A1 FAM212A GREM2 LRP5 PBX2 RGS14 SYNGR1
ALDH2 COL15A1 FAM46B GRHL2 LRP6 PBX3 RHOU SYPL1
ALK COL2A1 FGF10 GRWD1 LRRC8D PBX4 RNF41 TBC1D5
ALX1 COL5A1 FGF15 GSC MAFB PCDH10 ROBO1 TBX1
ALX4 COLEC11 FGF19 GSTP1 MARVELD1PCDH18 RPE65 TBX22
AMDHD2 CRABP1 FGF20 HAND2 MASP1 PCNA RTF1 TES
ANKRD50 CRABP2 FGF3 HDAC4 MDK PDE7A RUNX2 TFAP2A
AOX1 CRIP2 FGF8 HES1 MECOM PDGFRA RXRA TFAP2B
AP2A1 CSF1R FGFR1 HES3 MED12 PEPD RXRG TFAP2C
AQP7 CTR9 FGFR2 HES4 MEF2A PHACTR4 SALL4 TFAP2E
ARG1 CTSB FGFRL1 HHIP MEF2C PHLDA1 SDC4 TFEC
ASPM CTSC FLNC HIF1A MEIS1 PHOX2B SEMA3C TGFB2
ATIC CXCR4 FLRT3 HOXA1 MEIS3 PIAS2 SEMA3D TGFB3
ATOH8 CYB5A FMOD HOXA2 MITF PITX2 SEMA3F TGFBI
ATP1B3 CYP26A1 FMR1 HOXB1 MOCOS PKNOX1 SFRP1 TMEM243
ATP6V1A CYP26C1 FOXC1 HOXB2 MPV17 PLCB3 SFRP5 TNC
B3GAT1 CYTH1 FOXC2 HOXB3 MREG PLCG2 SHH TRAF4
BARX1 D4ADT9 FOXD1 HTR2B MSX1 PLSCR1 SKIDA1 TRPM3
BCMO1 DACH1 FOXD2 ID2 MSX2 PMEL SLC16A1 TSPAN8
BHLHE40 DCT FOXD3 ID3 MYC PNP SLC1A3 TTC8
BHLHE41 DDX21 FOXD4 IGDCC3 MYCN POLD1 SLC22A7 TWIST1
BMP2 DEGS1 FOXD4L1 IGFBP3 NAV3 POU3F3 SLC24A4 TWIST2
BMP4 DERA FOXD4L2 IL17RD NES PPAT SLC40A1 TWIST3
BMPER DFNA5 FOXD4L4 IMPDH1 NEUROD4 PRDM1 SLC45A2 UBE2I
BMPR1A DISC1 FOXD4L5 IRX1 NEUROG1 PRDM12 SLC4A1 VENTX
BTBD6 DLG1 FOXD4L6 ISL1 NRARP PRDX1 SLC4A2 VGLL2
C10orf11 DLL1 FOXD5 ITGA9 NRG1 PRIM1 SLMAP WNT1
CCND1 DLX2 FOXI1 ITGB1 NRG2 PROM1 SMAD4 WNT10A
CD200 DPYSL2 FOXS1 ITPKC NRP1 PTGIS SMARCA4 WNT11
CDCA7 DPYSL3 FRZB JUNB NRP2 PTRH2 SMO WNT3A
CDH2 DPYSL4 FSCN1 KAT6A NRTN PTTG1IP SNAI1 WNT5A
CDH6 DPYSL5 FZD3 KCTD15 NUSAP1 RAB11FIP2 SNAI2 WNT5B
CDON DSTN FZD7 KIT OCRL RAB12 SOX10 WNT8A
CERS1 DTNBP1 GADD45B KITLG olfm2a RAB32 SOX11 WTIP
CFL1 EDN1 GART KLF2 OSR1 RAB3C SOX4 XBP1
CFL2 EDN3 GATA3 KRT18 OSR2 RAB7A SOX8 ZBTB10
Gene Symbol
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Table 2.2 Traveling Ratios of Paused Neural Crest-Associated Genes
41
Table 2.2 (Continued)
RefSeq.ID Gene Symbol Average DMSO TR
Average 
Leflunomide TR
Average 
A77726 TR
TR Fold Change 
Leflunomide
TR Fold Change 
A771726
NM_001167882 ANKRD50 1.84 7.78 6.62 4.24 3.61
NM_020337 ANKRD50 1.84 7.78 6.62 4.24 3.61
NM_053056 CCND1 0.86 1.87 2.50 2.18 2.91
NM_001792 CDH2 2.21 9.23 11.65 4.17 5.27
NM_017780 CHD7 0.83 4.62 17.51 5.56 21.07
NM_133467 CITED4 3.60 4.76 8.51 1.32 2.36
NM_001908 CTSB 0.30 2.01 0.54 6.81 1.81
NM_147780 CTSB 0.30 2.01 0.54 6.81 1.81
NM_147781 CTSB 0.30 2.01 0.54 6.81 1.81
NM_147782 CTSB 0.30 2.01 0.54 6.81 1.81
NM_147783 CTSB 0.30 2.01 0.54 6.81 1.81
NM_001127453 DFNA5 2.77 4.30 4.33 1.55 1.56
NM_001127454 DFNA5 2.97 5.22 3.19 1.76 1.08
NM_004403 DFNA5 2.97 5.22 3.19 1.76 1.08
NM_000399 EGR2 0.54 1.81 2.41 3.38 4.51
NM_001136177 EGR2 0.54 1.81 2.41 3.38 4.51
NM_001136179 EGR2 0.54 1.81 2.41 3.38 4.51
NM_052943 FAM46B 0.37 0.83 1.35 2.26 3.69
NM_001004356 FGFRL1 0.41 0.00 1.90 0.00 4.63
NM_001004358 FGFRL1 0.41 0.00 1.89 0.00 4.62
NM_021923 FGFRL1 0.41 0.87 0.00 2.12 0.00
NM_004472 FOXD1 2.28 6.54 3.37 2.87 1.48
NM_000514 GDNF 0.33 1.02 1.35 3.10 4.10
NM_001190468 GDNF 3.59 1.03 0.41 0.29 0.11
NM_001190469 GDNF 3.59 1.03 0.41 0.29 0.11
NM_199231 GDNF 0.97 0.32 0.00 0.33 0.00
NM_002167 ID3 0.16 0.74 0.36 4.62 2.26
NM_000598 IGFBP3 0.75 1.96 6.02 2.60 8.00
NM_001013398 IGFBP3 0.75 1.96 6.02 2.60 8.00
NM_001142573 IMPDH1 2.23 8.26 4.78 3.70 2.14
NM_001142574 IMPDH1 2.23 8.26 4.78 3.70 2.14
NM_001142575 IMPDH1 2.23 8.26 4.78 3.70 2.14
NM_001099412 KAT6A 1.47 4.47 6.49 3.04 4.42
NM_001099413 KAT6A 1.47 4.47 6.49 3.04 4.42
NM_006766 KAT6A 1.47 4.47 6.49 3.04 4.42
NM_000224 KRT18 3.99 4.50 13.59 1.13 3.40
NM_199187 KRT18 2.04 3.44 11.23 1.69 5.51
NM_017947 MOCOS 3.66 5.34 9.30 1.46 2.54
NM_002449 MSX2 0.94 12.55 8.46 13.32 8.98
NM_003872 NRP2 2.39 7.55 5.54 3.17 2.32
NM_018534 NRP2 2.19 6.78 5.19 3.10 2.37
NM_201264 NRP2 1.92 6.91 4.92 3.61 2.57
NM_201266 NRP2 2.39 7.55 5.54 3.17 2.32
NM_201267 NRP2 2.19 6.78 5.19 3.10 2.37
NM_201279 NRP2 2.39 7.55 5.54 3.17 2.32
NM_023923 PHACTR4 2.14 38.32 8.86 17.87 4.13
NM_006928 PMEL 5.20 14.95 12.33 2.88 2.37
NM_014904 RAB11FIP2 1.12 11.32 8.10 10.10 7.22
Table 2.2 (Continued)
RefSeq.ID Gene Symbol Average DMSO TR
Average 
Leflunomide TR
Average 
A77726 TR
TR Fold Change 
Leflunomide
TR Fold Change 
A771726
NM_001242826 RNF41 6.31 10.73 15.27 1.70 2.42
NM_005785 RNF41 7.44 19.46 18.60 2.61 2.50
NM_194358 RNF41 7.44 19.46 18.60 2.61 2.50
NR_040053 RNF41 7.44 19.46 18.60 2.61 2.50
NM_001199692 SLC4A2 0.83 1.09 1.46 1.32 1.77
NM_001199693 SLC4A2 0.54 2.06 0.28 3.79 0.52
NM_003040 SLC4A2 0.26 2.56 1.13 9.83 4.34
NM_007159 SLMAP 1.39 3.43 3.97 2.47 2.86
NM_001128844 SMARCA4 4.01 9.01 8.04 2.25 2.01
NM_001128849 SMARCA4 0.27 0.84 2.13 3.08 7.84
NM_003072 SMARCA4 4.01 9.01 8.04 2.25 2.01
NM_001142298 SQSTM1 0.23 0.30 0.47 1.32 2.08
NM_001142299 SQSTM1 0.27 0.63 0.80 2.38 2.99
NM_001145454 STMN1 0.74 7.02 1.89 9.43 2.54
NM_005563 STMN1 0.34 4.19 0.89 12.16 2.59
NM_203401 STMN1 0.33 7.66 0.86 23.12 2.58
NM_001032280 TFAP2A 3.65 2.00 12.79 0.55 3.51
NM_003220 TFAP2A 0.61 1.82 0.48 2.97 0.79
NM_003222 TFAP2C 0.45 2.04 0.96 4.53 2.13
NM_004295 TRAF4 0.46 0.90 3.48 1.95 7.57
NM_003412 ZIC1 3.58 13.64 17.25 3.81 4.82
 We also examined how paused genes might be differentially regulated from unpaused 
genes (fold change in TR < 0.7 drug versus DMSO). From each gene list, we determined 
enrichment scores for transcription factor binding motifs using the Transcription Factor Affinity 
Prediction (TRAP) program (Thomas-Chollier et al., 2011). After which, we shortlisted motifs that 
were significantly enriched for paused genes in both the A771726 and leflunomide GRO-seq 
data set, but were not enriched in the unpaused genes from these two data sets. We obtained 
motifs for a number of transcription factors that are enriched in the paused versus unpaused gene 
sets (Figure 2.10F). As expected, we found that MYC target genes are preferentially paused, as 
highlighted by the pioneering study on leflunomide and melanoma (White et al., 2011). MYC is 
required for neural crest development and regulates transcriptional pause release in embryonic 
stem cells (Hong et al., 2008; Rahl et al., 2010). In addition, PAX3 targets also seem to be 
preferentially paused. Mutations in PAX3 in humans results in Waardenburg syndrome, a disease 
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characterized by deafness and pigment defects caused by problems in the embryonic neural crest 
(Baldwin et al., 1992; Tassabehji et al., 1992; Wollnik et al., 2003). PEA3, the targets of which are 
also paused, upregulates FAK to induce melanoma metastasis and regulates smooth muscle cell 
differentiation from the neural crest (Huang et al., 2011; Li et al., 2013b). DHODH inhibition seems 
to preferentially pause genes regulated by key neural crest-associated transcription factors.
Leflunomide Induces HEXIM1 to Sequester P-TEFb Away From Paused Gene Promoters
 HEXIM1 has recently been shown to bind gene promoter regions on chromatin (Ji et al., 
2013), so we investigated if HEXIM1 occupancy is modulated by leflunomide. We performed 
ChIP-seq for HEXIM1 and CDK9 to determine their respective binding regions in the A375 cells 
treated with either DMSO or A771726 for 48 hrs. Meta-gene analysis on the 2,003 paused genes 
from GRO-seq (Figure 2.10B) demonstrates that HEXIM1 and CDK9 are co-localized at the 
promoters in the A375 cells (Figures 2.11A and 2.11B). Furthermore, ChIP-seq region plots for 
HEXIM1 and CDK9 binding throughout the genome based on the union of HEXIM1 and CDK9 
binding regions in the DMSO control show co-binding of HEXIM1 with CDK9 at the same regions 
(Figure 2.11C). HEXIM1 seems to poise CDK9 at gene promoters for a quick release to the 
transcriptional machinery when required. Drug treatment causes a decrease in both HEXIM1 and 
CDK9 occupancy on chromatin (Figures 2.11A, 2.11B and 2.11C). This postulates that the drug 
induces the 7SK snRNP to sequester P-TEFb away from chromatin to inhibit the transition from a 
paused state to productive elongation.
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Figure 2.11 HEXIM1 Responds to DHODH Inhibition by Sequestering P-TEFb Away from 
Promoters
(A) Metagene analysis of genes with TR < 7.5 in the GRO-seq experiment for HEXIM1 binding 
regions determined by HEXIM1 ChIP-seq in DMSO or A771726 (25 μM for 48 hrs) conditions 
in the A375 cells. (B) Metagene analysis of genes described in (A) for CDK9 binding regions 
determined by CDK9 ChIP-seq in DMSO or A771726 (25 μM for 48 hrs) conditions in the A375 
cells. (C) ChIP-seq region plots representing the distribution of regions bound by HEXIM1 and 
CDK9 in A375 cells, treated with either DMSO or 25 μM A771726 for 48 hrs, −2.5 and +2.5 kb 
relative to all HEXIM1 bound sites in the DMSO-treated A375 cells.
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Discussion
 Leflunomide can act as an efficient anti-melanoma drug, both on its own and in synergy 
with vemurafenib (White et al., 2011). The combination of these two drugs is currently in a 
Phase II clinical trial for metastatic melanoma. Leflunomide is a DHODH inhibitor that affects 
pyrimidine biosynthesis, resulting in a reduction in productive transcription elongation. A 
significant transcriptional reduction is induced in genes involved in cell proliferation and cell cycle, 
thereby slowing the growth and proliferation of the neural crest and melanoma. However, the 
mechanism of how a shortage of nucleotides through DHODH inhibition can eventually lead to 
a transcriptional pause is unclear. Our work presented here demonstrates an important role for 
HEXIM1 in regulating the transition of paused RNA Pol II to a state of productive elongation.
HEXIM1 can suppress melanoma
 Even though we established that HEXIM1 is largely responsible for leflunomide’s anti-
melanoma effect through inhibiting productive transcription elongation, HEXIM1 alone has the 
ability to effectively suppress melanoma regardless of DHODH inhibition. HEXIM1 was previously 
discovered as a significantly upregulated gene upon treatment of cells with hexamethylene bis-
acetamide (HMBA) (Ouchida et al., 2003). HMBA is a bipolar compound that was found to induce 
differentiation in a variety of cancer cell lines and primary human cancer cell cultures, instead of the 
usual cytotoxicity caused by prominent chemotherapies (Marks and Rifkind, 1989). Upregulation 
of HEXIM1 therefore seems to be involved in the transition of cancer cells from the proliferative to 
a differentiating state. Since then, there have been a number of studies illustrating the importance 
of upregulating HEXIM1 in suppressing breast cancer (Ketchart et al., 2013; Wittmann et al., 
2003, 2005; Yeh et al., 2013) and prostate cancer (Mascareno et al., 2012). Furthermore, LARP7, 
a component of the 7SK snRNP complex that includes HEXIM1, is frequently mutated in gastric 
cancer (Cheng et al., 2012b; He et al., 2008; Mori et al., 2002). In these studies, the mechanism 
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of tumorigenic transformation and progression is the decreased ability of the 7SK snRNP to form, 
resulting in dysfunctional P-TEFb sequestration and consequently causing an upregulation in 
transcription elongation at tumorigenic genes. Furthermore, there have been recent efforts to 
develop inducers of HEXIM1 as anti-cancer drugs (Zhong et al., 2014).
 HEXIM1 likely plays an important role in inhibiting cellular transformation to the 
tumorigenic state in melanoma as well. This is supported by the fact that HEXIM1 expression is 
significantly downregulated in a significant percentage of human melanoma samples. In addition, 
overexpressing HEXIM1 in vivo can suppress melanoma in our zebrafish melanoma model. By 
downregulating HEXIM1, tumors can aberrantly transcribe cell proliferation and metastatic genes 
without the availability of the 7SK snRNP to regulate them.
 The ability for HEXIM1 to respond to cellular stress and negatively regulate transcription 
has great significance in tumorigenesis. Using leflunomide to create a state of cellular stress 
owing to nucleotide starvation upregulates HEXIM1, resulting in a transcriptional pause at a broad 
spectrum of genes associated with survival and proliferation. Metabolic drugs such as leflunomide 
that cause cellular stress and induce HEXIM1 can therefore pause numerous highly expressed 
genes simultaneously, targeting multiple pathways to halt the progression of cancer. Inducing 
the HEXIM1 stress pathway could therefore provide a multi-pronged gene expression approach, 
through modulating transcription elongation directly, to treat cancer.  It can be argued that JQ1, 
a BRD4 inhibitor that causes a more rapid upregulation of HEXIM1 to trigger a transcriptional 
pause (Bartholomeeusen et al., 2012), might be better suited than leflunomide to treat melanoma. 
The fact that JQ1 targets BRD4 regardless of cell type (Delmore et al., 2011; Filippakopoulos et 
al., 2010) means it is much less selective. Each cell type may have an Achilles’ heal for stress, 
and the neural crest seems to be particularly sensitive to low nucleotides, illustrated by patients 
with Miller’s syndrome who harbor mutations in DHOHD and have neural crest defects (Ng et al., 
2010).  Even though leflunomide possesses slower kinetics in upregulating HEXIM1, possibly 
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because it takes some time for cells to become nucleotide starved, it seems more useful in 
targeting neural crest-derived cancers because of the innate sensitivity of the neural crest to 
nucleotide stress. Other cell types may be susceptible to different cellular stresses, and respond 
in a similar manner by activating HEXIM1, inducing transcriptional pausing to help the cell repair. 
It is particularly interesting and worthwhile to study such dependencies in other cancers and 
utilize the appropriate drugs to target these cell types specifically.
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Materials and Methods
Cell Culture
 Human A375 malignant melanoma cells (ATCC) are grown on standard tissue culture plates 
in filter sterilized DMEM (Life Technologies) with 10% heat-inactivated FBS (Atlanta Biologicals), 
1X GlutaMAX (Life Technologies) and 1% Penicillin-Streptomycin (Life Technologies).
Drug Treatment
 Zebrafish embryos were treated with leflunomide at 50% epiboly in E3 embryo media and 
fixed at 24 hpf and 2 dpf for further analysis. A375 human melanoma cell lines were treated at 
various time points. Drugs used were leflunomide (Enzo Life Sciences) and A771726 (Enzo Life 
Sciences).
Morpholino Injection
 Morpholinos were obtained from Gene Tools, LLC, and injected into the yolk of the 1-cell 
stage embryo. Morpholinos were injected in a volume of 1 nL containing 8 ng of hexim, 8 ng of 
control, 10 ng of bcdin3 and 12 ng of larp7 morpholinos. Bcdin3 and larp7 morpholinos were 
previously published (Barboric et al., 2009). Morpholino sequences are: 
hexim TAATAAGCTCCATAACTGCACACTC
hexim control TAATAGGCTCAATACCTGTACAATC 
larp7 ATTAATAAAGTTACATACATCCATC
bcdin3 CATGTTTCTGTGGTCTTACCTTAAT
RNA Extraction and Quantitative RT-PCR Analysis
 RNA isolation was performed using TRIzol (Life Technologies), and subsequently treated 
with the TURBO DNA-free kit (Life Technologies). cDNA was synthesized with the SuperScript III 
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Kit (Life Technologies).  Quantitative PCR was performed on the iQ5 real-time PCR machine using 
the Ssofast EvaGreen Supermix (BioRad). The ∆∆Ct method was used for relative quantification. 
RT-PCR primers are:
hexim forward: 5’-CAAACACGAGATTTGAGTTAAACG-3’
hexim reverse: 5’-CTCGTCCGATAATCTCTCTGC-3’
HEXIM1 forward: 5’-GACCTGGGAAGAGAAGAAAAAG-3’
HEXIM1 reverse: 5’-GAGGAACTGCGTGGTGTTATAG-3’
gapdh forward: 5’-GTGGAGTCTACTGGTGTCTTC-3’
gapdh reverse: 5’-GTGCAGGAGGCATTGCTTACA-3’
GAPDH forward: 5’-AAGGTGAAGGTCGGAGTCAA-3’
GAPDH reverse: 5’-AATGAAGGGGTCATTGATGG-3’
Antibodies
 The HEXIM1 antibody from Abcam (ab25388) was used for western blots, co-
immunoprecipitation and immunohistochemistry. IgG normal rabbit control antibody for Co-IP 
was from Millipore (12-370). Western blot antibodies used were BCDIN3 (ab139562), LARP7 
(ab105682), CDK9 (ab76320), CCNT1 (ab2098) and RNAPII Ser-2 phosphorylation (ab 5095) 
from Abcam, as well as RNAPII (sc-899X) from Santa Cruz Biotechnology and β-Actin (A2228) 
from Sigma. Western antibodies used in the glycerol gradients were CDK9 (C-20) (sc-484) and 
CCNT1 (sc-10750) from Santa Cruz.
Glycerol Gradients 
 Glycerol gradients (10%-30%) were established by pipetting 2 mL of each glycerol 
fraction (10, 15, 20, 25 and 30% v/v) in MS buffer A into centrifugation tubes (Beckman 331372). 
Gradients were formed by standing for 6 s at 4° C. A375 cells (106) were untreated or treated 
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with A771726 for indicated periods of time and lysed in 0.6 mL of buffer A (20 mM HEPES-KOH, 
pH7.8, 0.2 M KCl, 0.2 mM EDTA, 0.5% NP40) containing protease inhibitors (Pierce) and RNase 
OUT (Invitrogen) for 30 mins at 4°C. Lysates were centrifuged at 14,000 rpm for 10 minutes and 
supernatants were loaded into tubes with preformed glycerol gradients. Protein complexes were 
then fractionated by centrifugation in an SW40T1 rotor (Beckman) at 38,000 rpm for 21 hrs. 
Ten fractions (1 mL) were collected, precipitated with trichloracetic acid and analyzed with the 
indicated antibodies by western blotting.
HEXIM1 Co-immunoprecipitation
 Co-IP was performed using the Dynabeads Protein G Immunoprecipitation Kit with the 
DynaMag-2 Magnet (Life Technologies). Adherent cells plated on 10 cm culture plates were placed 
on ice and washed twice with ice-cold 1X PBS. 1 mL of ice-cold RIPA lysis and extraction buffer 
(Thermo Scientific), containing protease (Sigma) and phosphatase (Thermo Scientific) inhibitor 
cocktails, was added to each plate. Cells were scraped into the RIPA buffer and allowed to rotate 
in microfuge tubes at 4°C for 30 mins. Cell suspensions were then centrifuged at 12,000 rpm at 
4°C for 10 mins to pellet cell debris. Protein concentrations of cell lysates were then measured 
by the DC Protein Assay (Bio-rad) to normalize all samples. Beads were prepared by washing 3 
times with 5% Bovine Serum Albumin (Sigma) in 1X PBS on the magnetic stand. For 2 mg total 
protein, 33 μL of beads and 8 μg of antibody were used. Cell lysates were pre-cleared with beads 
for 1 hr rotating at 4°C. Beads used for pre-clearing were isolated by magnet and the pre-cleared 
cell lysate were transferred to a new microfuge tube. This is followed by overnight incubation of 
the cell lysate with either the HEXIM1 antibody (Abcam) or IgG control (Millipore) at 4°C. Next, 
fresh beads were added to the lysate-antibody mix for a 2 hr to overnight incubation at 4°C. 
Protein-bead complexes were then washed 4 times with ice-cold lysis buffer, which consisted of 
cycles of resuspending beads in wash buffer and isolating beads on the magnet. The final wash 
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is then removed from the beads and the beads were boiled in 50 μL Laemmli Buffer (Bio-rad) to 
elute proteins. Eluates were analyzed by western blotting.
Melanoma Immunohistochemical H-scoring
 The human melanoma tissue microarray ME1004b (Biomax) used for IHC contains 62 
cases of malignant melanoma, 20 cases of metastatic malignant melanoma and 18 cases of 
nevus tissue. In an attempt to accurately describe the extent of immunohistochemical staining 
of a tumor, the degree of IHC staining, if any, in each sub-cellular compartment in tumor cells is 
captured for each analyte. This algorithm includes capturing the percentage of tumor cells stained 
at each intensity level. A semi-quantitative intensity scale ranging from 0 for no staining to 3+ for 
the most intense staining is used.  All of this information can be analyzed separately or used to 
calculate a variable, more continuous than simply Positive versus Negative, called the H-Score 
(McClelland et al., 1990).  This score is more representative of the staining of the entire tumor on 
the section.  Although given sections may share the same simple intensity score, there clearly is a 
difference between a 3+ case with only 10% of the cells staining as compared to a 3+ case where 
greater than 90% of the cells are staining.  This difference is easily picked up using the H-Score 
method. An H-Score is typically calculated for staining of each sub-cellular compartment for both 
normal and tumor cells using the following formula; H-Score  = (% at 0) * 0 + (% at 1+) * 1 + (% at 
2+) * 2 + (% at 3+) * 3. Thus, this score produces a continuous variable that ranges from 0 to 300. 
MiniCoopR Assay
 The miniCoopR vector sequence and construction was previously described (Ceol et 
al., 2011). Human HEXIM1 and zebrafish hexim miniCoopR clones were created by MultiSite 
Gateway recombination (Invitrogen) using full-length open reading frames. HEXIM1-4A and -4D 
clones were created by site-directed mutagenesis using the QuikChange II XL Mutagenesis Kit 
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(Agilent). 25 pg of each miniCoopR clone and 25 pg of mRNA encoding the Tol2 transposase were 
microinjected into one-cell zebrafish embryos generated from an incross of Tg(mitfa:BRAFV600E); 
p53-/-; mitfa-/- zebrafish. Rescued animals were scored weekly for the presence of visible tumors.
Zebrafish Genotyping
 Adult transgenic zebrafish for WT HEXIM1, HEXIM1-4A and -4D were genotyped by tail 
fin clipping. Genomic DNA was extracted by incubating fin clips in 25 μL of alkaline lysis buffer (25 
mM NaOH, 0.2 mM disodium EDTA) for 1 hr at 95°C. The mixture was then quenched on ice with 
25 μL of neutralization solution (Tris-HCL 40 mM) added and mixed by pipetting. Insoluble debris 
was pelleted by centrifuging for 5 min at 1,000 rpm. The supernatant containing genomic DNA was 
subjected to PCR with primers: HEXIM1 forward: 5’-CTCAAAACCGGCCTGTACTC-3’, HEXIM1 
reverse: 5’-TCCTTGATGAGCTCCTGCTT-3’ to amplify a 212 bp region of human HEXIM1 which 
contains the 4A and 4D mutations. PCR products were then sent for sequencing.
GRO-seq Sample Preparation and Sequencing
 GRO-seq was performed as previously described (Kim et al., 2013), except conditions were 
optimized to A375 cells, and libraries were multiplexed to conduct high-throughput sequencing 
in one lane. One million A375 cells per condition were treated with DMSO, 25 μM leflunomide, 
or 25 μM A771726 in duplicate.  After a 48 hr treatment, cells were washed, swelled, and lysed 
in lysis buffer with a reduced amount of IGEPAL detergent (composition: 10 mM Tris-Cl pH 7.5, 
2 mM MgCl2, 3 mM CaCl2, 10% glycerol, 2 U/mL SUPERasin (Ambion), and 0.25% IGEPAL). 
Cells were frozen down, nuclear run-on reaction was performed, and nascent RNA was isolated. 
Adaptors were ligated the same as before, however, TruSeq small RNA sample prep kit adapters 
and primers (Illumina) were used to make the samples suitable for multiplexing (indexes 1 and 
2, 3 and 4, and 5 and 6 were used for DMSO, leflunomide, and A771726 treated nascent RNA 
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libraries, respectively). The PCR reaction was run for 18 cycles. The indexed libraries were purified 
on a 6% native polyacrylamide gel, and were cut out between 150 and 300 bp.  The concentration 
of the isolated libraries was estimated with a high-sensitivity DNA chip from Agilent according 
to the manufacturer’s protocol and libraries were mixed in equal quantities and sequenced on 
Illumina Hi-Seq2000. Index sequences from multiplexed primers were used to identify treatment 
group and reads were demultiplexed using a perl script. 
GRO-seq Data Analysis
 GRO-seq data were processed as described in (Sigova et al., 2013). Briefly, for each 
replicate of DMSO (control), Leflunomide and A771762 treated samples, reads were trimmed at 
the 3′ends to remove any linker sequence contamination. Trimmed reads for each sample were 
aligned to the hg18 version of the human genome using Bowtie 0.12.9 with parameters -k 1 -m 
10 -n 2 --best --strata. RNA repeats were then filtered out from the alignments using bedtools. 
Total number of sequenced, mapped, and filtered reads are shown in Table 2.3. Metagenes were 
created using the method described in (White et al., 2011). The average density of reads was 
calculated from the two biological replicates using respectively 5 fixed bins for the TSS -2 kb to 
TSS and TTS to TTS +2 kb regions, and 50 variable bins equally dividing the lengths of each 
gene. For each sample, the mean densities of reads were normalized to the read density at the 
promoter of the beta-Actin gene, which transcription is not modified by Leflunomide treatment, 
and expressed as a fraction of millions of mapped reads per base pair (rpm/bp). Read density at 
the promoters and within the gene bodies were respectively calculated as the read density within 
300 bp of the TSS, and the read density within the TSS +300 bp to the TTS +3 kb. Densities were 
normalized to the read density at the beta-Actin promoter for each sample. RNA Polymerase II 
Travelling ratios (TR) were calculated as described in (Rahl et al., 2010; White et al., 2011) as 
the ratio of read densities at the promoters over the read densities within the gene bodies for 
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each transcript in each sample. Average TRs were calculated from the TRs calculated in two 
experimental replicates. To quantify the effects of the drug treatment on the TRs, samples were 
compared using a Wilcoxon rank sum test. The read densities were calculated on the transcripts 
which have a TR in the DMSO control condition initially low (TR< 7.5), representing 22442 over 
47021 transcripts. For examples of affected and unaffected genes, the GRO-Seq read density 
profiles for single genes were plotted from -2 kb to TSS to TTS +2 kb. The y-axes shows the 
average reads per base per million total sample reads. The profile of DMSO, Leflunomide and 
A771726 treated samples are normalized based on the read density of the peak at the promoter 
region.
Sample Sequenced Mapped Filtered
DMSO_a 12174743 6235753 1314438
DMSO_b 15400969 6907706 1561337
Leflunomide_a 17119601 8792723 1970152
Leflunomide_b 20658238 9441667 1817574
A771762_a 27873749 14033458 2840767
A771762_b 24780556 11104376 2183387
Table 2.3 Number of Reads in the GRO-seq Datasets
HEXIM1 siRNA Knockdown in Cell Culture
 200,000 A375 cells were plated in 6-well plates in complete media and rested for 24 hrs. 50 
ng of HEXIM1 SMARTpool siRNAs (Thermo Scientific Bio) were then transfected into the cells via 
DharmaFECT 1 reagent (Fisher Scientific) following the recommended protocol accompanying 
the DharmaFECT reagent. Cells were incubated in transfection media containing 60 μM A771726 
for 48 hrs before protein was harvested for western blot.
55
Generation of Neural Crest Gene List
 Vertebrate neural crest-associated genes were identified by gene expression and gene 
ontology analyses. The zebrafish whole-mount mRNA expression database (http://zfin.org/cgi-
bin/webdriver?MIval=aa-xpatselect.apg) and the gene ontology database AmiGO (Carbon et al., 
2009) (http://amigo.geneontology.org) were queried for ‘neural crest’ search terms (databases 
were accessed by EvR on 10 September 2012). High-confidence human orthologs were predicted 
using the DRSC Integrative Ortholog Prediction Tool DIOPT (Hu et al., 2011) (http://www.flyrnai.
org/cgi-bin/DRSC_orthologs.pl). Only orthologs with the highest weighted prediction score were 
included on the neural crest-associated gene list.
GRO-seq Gene Motif Analysis
 Transcripts having a TR fold change > 1.3 were considered as paused and transcripts 
having a TR fold change < 0.7 were considered as unpaused. TSS +-300bp sequences of each 
list of transcript for each of the Leflunomide or A771762 drug treated condition were extracted. 
1500 randomly picked promoter sequences in each list were used as input for the Transcription 
Factor Affinity Prediction (TRAP) program using TRANSFAC vertebrates set of motifs, human 
promoters as the background model, and Benjamini-Hochberg as the multiple test for p-value 
correction (Thomas-Chollier et al., 2011). The transcription factor binding sequence motifs that 
were enriched with a corrected p-value < 1e-4 in the paused list of transcripts but not in the 
unpaused list of transcripts were selected and their motif logo were recovered from the TRANSFAC 
database (Matys et al., 2006).
ChIP-seq Sample Preparation and Sequencing
 ChIP-seq was performed as previously described (Lee et al., 2006), except growth 
conditions were optimized to A375 cells, and libraries were multiplexed to conduct high-throughput 
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sequencing in one lane. One hundred million A375 cells per condition were treated with DMSO 
or 25 μM A771726.  After a 48 hr treatment, cells were fixed in 11% formaldehyde and subjected 
to chromatin immunoprecipitation with HEXIM1 antibody (Abcam) or Cdk9 (C-20) antibody 
(Santa Cruz). 10 μL of input DNA and the entire volume of ChIP DNA samples were prepared for 
sequencing. The End-It DNA End-Repair Kit (Epicentre) was used to turn DNA overhangs into 
phosphorylated blunt ends and the Agencourt AMPure XP PCR Purification Kit (Beckman Coulter) 
was used to purify the resulting samples using a 1.8X ratio of beads to sample. Next, a single 
A in the 3’ end was added to samples using the Klenow Fragment enzyme (NEB) to allow for 
directional ligation and the AMPure Kit was again used to purify samples. Illumina adaptor oligos 
(1:10 dilution) were added to samples using the Quick Ligation Kit (NEB) and NEBNext Multiplex 
Oligos for Illumina Kit (NEB), and samples were purified with the AMPure Kit. Samples were then 
size-selected with the AMPure beads with a 0.9X bead to sample ratio. Multiplexing primers from 
the NEBNext Multiplex Oligos Kit were added during the 18-cycle PCR enrichment step, which 
utilized the Phusion High-Fidelity PCR Master Mix (NEB), to generate indexed libraries (multiplex 
indexes used were: 3 – DMSO Input, 4 – A771726 Input, 5 – DMSO Cdk9 IP, 6 – A771726 Cdk9 
IP, 9 – DMSO HEXIM1 IP, 10 – A771726 HEXIM1 IP). Indexed libraries were separated on a 
2% agarose gel. Products between 150-350 base pairs were excised and gel purified using the 
QIAquick Gel Extraction Kit (Qiagen). The concentration of the isolated libraries was estimated 
with a high-sensitivity DNA chip from Agilent according to manufacturer’s protocol and libraries 
were mixed in equal quantities and sequenced on Illumina Hi-Seq2000. Index sequences from 
multiplexed primers were used to identify treatment group and reads were demultiplexed using a 
perl script. 
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ChIP-seq Data Analysis
 All ChIP-seq data sets were aligned using Bowtie (version 0.12.2) (Langmead et al., 2009) 
to build version hg19 of the human genome with parameters “-k 2 -m 2 -n 2”. We used the MACS 
version 1.4.1 (Model-based analysis of ChIP-seq) (Zhang et al., 2008) peak finding algorithm 
to identify regions of ChIP-seq enrichment over background. A p-value threshold of enrichment 
of 1e-9 was used for all data sets with parameters “--keep-dup=2”. To obtain the normalized 
read density of ChIP-seq data sets in any region, ChIP-seq reads aligning to each region were 
extended automatically by MACS, and the density of reads per bp was calculated. The density of 
reads in each region was normalized to the total number of million mapped reads producing read 
density in units of reads per million mapped reads per bp (r.p.m./bp).
Heatmap Representation of ChIP-seq Read Density Profiles
 The merged regions of CDK9 DMSO control and HEXIM1 DMSO control were aligned at 
the center in the composite view of signal density profile. The enriched regions of CDK9 DMSO 
and HEXIM1 DMSO were first merged together if overlapping by 1 bp, resulting in a total of 9,230 
merged regions. The average ChIP-seq read density (r.p.m./bp) around 5 kb centered on the 
centers in 50 bp bin was next calculated and displayed. 
Meta Representation of ChIP-seq Read Density Profiles
 We first created density vectors for the list of transcribed genes with initial TR < 7.5 from 
the GRO-seq experiment. The densities in the promoter, gene body, and gene end region were 
placed into 320 bins to create a density vector. 60 fixed width bins for the -3000 to 0 promoter 
region, 200 variable bins equally dividing the length of the gene, and 60 fixed bins for the 0 to +3 
kb after transcript end region. The average ChIP-seq read density (r.p.m./bp) for each bin was 
next averaged and displayed. 
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Attributions
 I conceived the idea to perform metabolite profiling on leflunomide-treated A375 cells to 
determine changes in metabolism. In addition, I performed cell culture and metabolite extraction. M. 
Yuan and J. M. Asara ran my samples on the mass spectrometer utilizing the liquid chromatography-
based tandem mass spectrometry (LC-MS/MS) methodology. After which, I normalized the raw 
data and analyzed the processed data in Microsoft Excel and on the Metaboanalyst web server 
to generate the metabolite heatmap, fold changes, time course analysis and metabolite set 
enrichment analysis (MSEA). C. S. Santoriello optimized the nucleotide rescue experiment and 
performed the crystal violet cell number assay. I performed the real time RT-PCR analysis for 
the nucleotide rescue experiment and the western blots for HEXIM1 and ACTB, with technical 
assistance from R. D. Fogley.
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Introduction
 The primary function of leflunomide is to bind and inhibit DHODH, leading to a block in 
pyrimidine biosynthesis and a subsequent decrease in proliferation of neural crest and melanoma. 
Since leflunomide targets a metabolic process, we investigated how metabolism is affected by 
drug treatment by metabolite profiling. Metabolite profiling is highly analogous to microarray gene 
expression analysis, where the relative amounts of a number of metabolites in a cell are measured 
via targeted mass spectrometry under various conditions, in our case, with and without leflunomide. 
One can examine significant differences in metabolites with online tools in the Metaboanalyst web 
server (Xia et al., 2009, 2012). In addition to metabolite profiling, we examined how HEXIM1 
expression is regulated by primary metabolic changes induced by leflunomide.
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Results
Leflunomide Primarily Targets Pyrimidine Biosynthesis
 Leflunomide targets a key metabolic pathway, so we explored the changes in metabolism 
caused by the drug. We employed liquid chromatography-based tandem mass spectrometry (LC-
MS/MS) (Yuan et al., 2012) to perform metabolite profiling on A771726 treated A375 cells at 
various time points. From the heatmap profile, metabolites are unchanged by DMSO treatment at 
various time points, while A771726 treatment causes significant changes in multiple metabolites, 
particularly from 24 hrs onwards (Figure 3.1, Tables 3.1 and 3.2). The cut-off for a significant 
altered metabolite is at least a 2-fold change in relative levels with an accompanying p-value 
of less than 0.05 (Student’s two-tailed t-test). Metabolite Set Enrichment Analysis (MSEA) of 
significantly altered metabolites at the various time points indicates that pyrimidine biosynthesis 
and RNA transcription are significantly dysregulated at the 24, 48 and 72 hr time points (Figure 
3.2). These results demonstrate that the drug is specifically targeting pyrimidine biosynthesis as 
expected.
 Further analysis of pyrimidine biosynthesis and purine biosynthesis alone also reflects 
the specificity of the drug. Significant upregulation of the pyrimidine intermediate N-carbamoyl-L-
aspartate upstream of DHODH is already seen with 1 hr of drug treatment (Figure 3.3A). At later 
time points, there is significant upregulation of all metabolites upstream of DHODH and significant 
downregulation of metabolites downstream of DHODH (Figure 3.3A). Purine biosynthesis 
intermediates are hardly affected until 72 hrs of treatment. Furthermore, significant metabolite 
changes are primarily limited to pyrimidine intermediates before 48 hrs, after which secondary 
effects are observed (Figure 3.1, Tables 3.1 and 3.2). These metabolite profiles highlight the high 
degree of specificity of A771726 to pyrimidine biosynthesis.
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 Figure 3.1 Metabolite Profiling of DHODH Inhibition in A375 Cells
LC-MS/MS metabolite profile of the A375 cell line treated with DMSO or 25μM A771726 over 
various time points.
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Time Point Metabolite Fold Change P-value
0.5 hr N-carbamoyl-L-aspartate 6.53 1.88E-05
dTTP 2.32 6.45E-03
Trehalose-6-Phosphate 2.32 9.12E-03
1 hr N-carbamoyl-L-aspartate 14.95 7.92E-03
Putrescine 3.15 5.74E-03
24 hr N-carbamoyl-L-aspartate 187.36 2.42E-03
Dihydroorotate 57.33 1.29E-03
2-Isopropylmalic acid 19.13 9.91E-03
Cystine 10.26 6.72E-03
Methylnicotinamide 3.73 2.85E-02
Aspartate 3.00 2.56E-03
Carbamoyl phosphate 2.94 7.27E-04
Allantoin 2.50 2.36E-03
dCDP 2.06 6.78E-04
Maleic acid 2.06 9.95E-04
48 hr N-carbamoyl-L-aspartate 180.62 1.52E-03
2-Isopropylmalic acid 21.28 1.05E-03
Dihydroorotate 15.70 5.85E-04
Aspartate 6.71 1.68E-03
N-acetyl spermidine 4.89 4.25E-03
Deoxyinosine 4.71 1.91E-02
Adenosine 5-phosphosulfate 2.87 2.20E-02
Fumarate 2.82 4.56E-04
2-keto-isovalerate 2.75 1.35E-03
Maleic acid 2.70 1.37E-04
Guanosine 2.22 1.91E-02
Allantoin 2.16 7.16E-03
Imidazole 2.08 4.87E-02
72 hr N-carbamoyl-L-aspartate 64.62 7.85E-04
Dihydroorotate 24.13 3.65E-03
2-Isopropylmalic acid 15.87 1.01E-03
Cystine 5.60 6.44E-03
Phosphoenolpyruvate 5.19 1.98E-02
Aspartate 4.32 1.29E-02
2,3-Diphosphoglyceric acid 4.15 6.07E-03
3-phosphoglycerate 3.87 8.01E-03
Ascorbic acid 3.53 1.82E-02
Glycerate 3.40 2.20E-04
Carbamoyl phosphate 3.02 2.27E-04
Asparagine 2.83 4.97E-02
Allantoin 2.62 5.23E-04
Anthranilate 2.59 7.70E-03
N-acetyl-glucosamine-1-phosphate 2.41 2.03E-03
Guanine 2.23 4.95E-02
Table 3.1 List of Metabolites Significantly Upregulated by A771726 Treatment
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Table 3.2 List of Metabolites Significantly Downregulated by A771726 Treatment
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Time Point Metabolite Fold Change P-value
0.5 hr 2,3-dihydroxybenzoic acid -6.04 1.34E-02
Shikimate -2.00 1.46E-02
1 hr Adenosine -2.76 4.10E-02
Inosine -2.50 1.24E-02
24 hr UDP -28.75 1.38E-02
UTP -16.92 6.94E-03
CTP -16.39 8.69E-03
UDP-D-glucose -6.90 4.72E-03
UDP-N-acetyl-glucosamine -5.24 3.18E-03
Trehalose-6-Phosphate -3.97 2.52E-02
Cystathionine -2.96 5.44E-03
GTP -2.62 1.01E-02
Guanidoacetic acid -2.17 5.87E-03
3-phospho-serine -2.10 9.23E-03
Citraconic acid -2.07 8.32E-03
dATP -2.06 2.64E-02
48 hr UTP -10.92 1.02E-02
CTP -9.43 1.20E-02
UDP -7.93 8.80E-03
dCTP -4.95 4.28E-02
UDP-D-glucose -4.67 3.55E-03
UDP-N-acetyl-glucosamine -3.68 6.13E-04
Kynurenic acid -3.44 1.93E-03
dTTP -3.30 4.52E-03
N-acetyl-glutamate -3.04 1.67E-02
Coenzyme A -2.63 1.09E-02
Glutathione -2.60 3.53E-02
UMP -2.59 7.28E-03
Fructose-1,6-bisphosphate -2.40 3.81E-03
dTMP -2.35 3.45E-02
Glutathione -2.32 2.22E-02
Geranyl-PP -2.27 7.95E-03
O-acetyl-L-serine -2.08 3.85E-02
Putrescine -2.06 3.07E-02
Sedoheptulose-1,7-bisphosphate -2.02 3.93E-03
Table 3.2 (Continued)
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Time Point Metabolite Fold Change P-value
72 hr Aminoimidazole carboxamide ribonucleotide -10.55 1.66E-03
Cystathionine -10.35 2.37E-04
Glutathione -6.53 9.09E-04
UTP -6.07 2.07E-05
Phosphorylcholine -5.08 1.72E-06
dTTP -5.05 1.69E-02
dihydroxy-acetone-phosphate -4.96 4.28E-02
Geranyl-PP -4.47 1.53E-02
Kynurenic acid -4.47 6.76E-03
UDP -4.40 1.36E-02
O-acetyl-L-serine -4.19 1.00E-02
CTP -4.12 5.36E-03
GTP -3.95 4.67E-02
UDP-D-glucose -3.89 1.71E-03
4-aminobutyrate -3.52 1.40E-02
Trehalose-6-Phosphate -3.17 3.47E-02
N-acetyl-glutamate -3.09 1.64E-02
Taurine -2.78 3.05E-03
D-glyceraldehdye-3-phosphate -2.72 1.49E-02
Glucono-δ-lactone -2.48 1.03E-01
Glutathione disulfide -2.39 1.98E-02
2-hydroxygluterate -2.37 7.52E-04
Guanidoacetic acid -2.32 1.19E-02
Biotin -2.28 2.28E-02
IDP -2.16 2.98E-02
Fructose-6-phosphate -2.15 1.23E-02
Glutathione disulfide -2.13 2.27E-05
ATP -2.12 4.72E-02
Glucose-6-phosphate -2.07 9.97E-03
Cholesteryl sulfate -2.04 6.55E-03
Table 3.2 (Continued)
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A
D
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Time Point Enriched Pathways P-value
0.5 hr - -
1 hr - -
24 hr Pyrimidine Metabolism 1.76E-05
RNA Transcription 1.25E-03
48 hr Pyrimidine Metabolism 2.08E-06
RNA Transcription 3.47E-03
Aspartate Metabolism 8.41E-03
72 hr Gluconeogenesis 4.27E-06
Glycolysis 4.99E-06
RNA Transcription 7.99E-04
Pyrimidine Metabolism 2.25E-03
Figure 3.2 Pyrimidine Biosynthesis is Primarily Affected by Leflunomide
(A) Metabolite Set Enrichment Analysis (MSEA) was performed on a list of significantly altered
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(Continued) metabolites (> 2-fold change, p-value < 0.05) from A771726-treated A375 cells 
compared to DMSO controls at a 24 hr time point. The graph shows rank ordered metabolic 
pathways by p-value that are enriched by drug treatment. (B) MSEA performed after 48 hr of 
A771726 treatment. (C) MSEA performed after 72 hr of A771726 treatment. (D) Summary of 
significantly altered metabolic pathways (p-value < 0.01).
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Figure 3.3 HEXIM1 is Upregulated in Response to Low Nucleotide Levels Induced by 
DHODH Inhibition
(A) Profiling of pyrimidine and purine biosynthesis metabolites in A375 cells treated with 25 μM 
A771726 at 1 hr, 24 hr, 48 hr and 72 hr time points. (B) Real time RT-PCR on A375 cells treated
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HEXIM1 is Upregulated in Response to a Low Nucleotide State Induced by DHODH Inhibition
 Since leflunomide primarily perturbs pyrimidine biosynthesis, we examined if HEXIM1 
responds to this perturbation. A HEXIM1-luciferase reporter assay (Liu et al., 2014b) in A375 cells 
demonstrates that HEXIM1 is increasingly transcribed over time with the addition of A771726, with 
HMBA as a positive control for HEXIM1 induction (Figure 2.4E). In addition, the accompanying 
westerns show that HEXIM1 is only significantly unregulated 48 hrs after treatment (Figure 3.4). 
We also show that increased HEXIM1 expression induced by A771726 can be rescued by the 
addition of pyrimidine nucleotides to the cells (Figure 3.3B). Adding nucleotides alone does not 
alter HEXIM1 expression, suggesting that the role of HEXIM1 in transcriptional regulation is 
prominent in times of starvation and not in times of nucleotide excess.
 The effects on cell proliferation correlate with HEXIM1 expression, where a 50% reduction 
in cell number is observed only at the 72 hr time point where HEXIM1 protein is most differentially 
increased (Figures 3.3B and 3.3C). Taken together, these results indicate that the cells have to 
be sufficiently starved of nucleotides before HEXIM1 is activated to regulate transcription with a 
corresponding decrease in cell proliferation.
(Continued) with 25 μM A771726, a cocktail of 10 μg/mL pyrimidine nucleotides (UMP and CMP) 
and a combination of both A771726 and nucleotides to examine HEXIM1 expression at the 24 hr 
and 72 hr time point. Data is normalized to GAPDH. (C) Quantification of cell number changes at 
various time points of A375 cells treated as in (A). 
HEXIM1
TBP
DMSO A771
1 hr 24 hr 72 hr48 hr
DMSO A771 DMSO A771 DMSO A771
Figure 3.4 HEXIM1 is Upregulated After Significant Nucleotide Depletion Following DHODH 
Inhibition
Western blot of HEXIM1 and TBP in nuclear extract of A375 cells treated with 25 μM A771726 at 
1 hr, 24 hr, 48 hr and 72 hr time points.
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Discussion
HEXIM1 Regulates Transcription in Response to Low Nucleotide Levels
 When cells are nucleotide starved, they are likely to slow their rate of transcription in 
order to conserve nucleotides till homeostasis returns. We suggest that one mechanism in which 
cells conserve nucleotides is to repress transcription elongation, which involves an upregulation 
of HEXIM1 to bind and sequester P-TEFb. Sequestration of P-TEFb prevents P-TEFb from 
phosphorylating RNA Pol II at its CTD Ser-2 sites. As a result, more RNA Pol II molecules remain 
paused at the initiation step of transcription. HEXIM1 expression is tightly linked to nucleotide 
levels, with decreasing levels triggering an increase in HEXIM1 expression. Cells can therefore 
take advantage of the transcriptional reprieve, provided by HEXIM1 inhibition of elongation, until 
nucleotides return to sufficient levels. After which, HEXIM1 returns to homeostatic levels, allowing 
transcription to return to normal. This suggests an elegant feedback mechanism, where cells are 
able to control transcription based on the amount of mRNA precursors available. Cells prefer 
to slow their growth rate via HEXIM1 downregulation of genes associated with cell cycle and 
proliferation in times of starvation, therefore conserving cellular resources until conditions become 
favorable for proliferation.
Regulating Transcription Elongation in Response to Cellular Stress
 Gene expression can be regulated at the level of chromatin structure, transcription initiation 
and elongation, but there are a number of advantages if transcription elongation is regulated as 
a direct consequence of nucleotide starvation or other cellular stresses. Studies have shown 
that a number of genes in the Drosophila embryo involved in key developmental pathways as 
well as heat shock genes are held in a paused state before induction as reviewed by Levine 
(Levine, 2011). At these genes, transcription has already been initiated as RNA Pol II has been 
successfully recruited to the promoters. However, RNA Pol II does not immediately transition to a 
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productive elongation phase and instead, remains paused on these promoters before receiving 
signals to induce productive elongation (Chopra et al., 2009; Levine, 2011; Muse et al., 2007; 
Zeitlinger et al., 2007). This allows RNA Pol II to be poised at genes that require rapid induction, 
saving the time needed for RNA Pol II to be recruited to the promoters to initiate transcription 
(Levine, 2011). In addition, chromatin can remain in an open state before elongation is induced 
(Levine, 2011). This sets up a system where cellular stress can induce a rapid and coordinated 
upregulation of genes to respond effectively to the stress.
 Such a system is highly beneficial to the organism as a quick and concerted response 
could limit the damage done by the stress. In the case of nucleotide starvation, unfavorable effects 
might include DNA damage, mis-expression of mRNA and protein, and possibly bioenergetic 
issues due to the lack of ATP and GTP. An immediate repression of non-essential genes by 
halting elongation through HEXIM1 sequestration of P-TEFb will allow for stress response genes 
to be expressed properly utilizing the remaining nucleotides available. In addition, once the stress 
is alleviated, the cell can return to homeostasis more rapidly, as RNA Pol II remains poised in a 
paused state at genes that were expressed before the stress. Inhibiting transcription elongation 
temporarily as a response to nucleotide starvation is therefore a viable mechanism to ensure a 
quick turnaround in terms of response to and recovery from cellular stress.
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Materials and Methods
Targeted Mass Spectrometry
 Samples were re-suspended using 20 μL HPLC grade water for mass spectrometry. 5 μL 
were injected and analyzed using a hybrid 5500 QTRAP triple quadrupole mass spectrometer 
(AB/SCIEX) coupled to a Prominence UFLC HPLC system (Shimadzu) via selected reaction 
monitoring (SRM) of a total of 256 endogenous water soluble metabolites for steady-state analyses 
of samples (Yuan et al., 2012). Some metabolites were targeted in both positive and negative 
ion mode for a total of 289 SRM transitions using positive/negative ion polarity switching. ESI 
voltage was +4900 V in positive ion mode and –4500 V in negative ion mode. The dwell time was 
3 ms per SRM transition and the total cycle time was 1.55 seconds.  Approximately 10-14 data 
points were acquired per detected metabolite. Samples were delivered to the mass spectrometer 
via hydrophilic interaction chromatography (HILIC) using a 4.6 mm i.d x 10 cm Amide XBridge 
column (Waters) at 400 μL/min. Gradients were run starting from 85% buffer B (HPLC grade 
acetonitrile) to 42% B from 0-5 minutes; 42% B to 0% B from 5-16 minutes; 0% B was held from 
16-24 minutes; 0% B to 85% B from 24-25 minutes; 85% B was held for 7 minutes to re-equilibrate 
the column. Buffer A was comprised of 20mM ammonium hydroxide/20 mM ammonium acetate 
(pH=9.0) in 95:5 water:acetonitrile. Peak areas from the total ion current for each metabolite SRM 
transition were integrated using MultiQuant v2.0 software (AB/SCIEX).
Metabolite Profile Analyses
 Relative intensities of metabolites were first normalized to the row average of the DMSO 0.5 
hr time point, followed by normalization to the median of the entire dataset. Heat map generation 
and clustering were performed on the MetaboAnalyst web server with Log transformation and 
Autoscaling (mean-centered and divided by the standard deviation of each variable) (Xia et al., 
2009, 2012). MSEA was also performed on the MetaboAnalyst web server with lists of metabolites 
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with fold change more than or equal to 2 in drug treatment compared to DMSO, with a Student’s 
two-tailed t-test p-value of less than 0.05 (Xia and Wishart, 2010). 
Nucleotide Rescue Experiment
 A375 cells were seeded in a 6 well plate. The following day culture media was replaced with 
fresh media containing 25 μM A771726 and/or a cocktail of 10 μg/mL uridine 5′-monophosphate 
(UMP, Sigma) and 10 μg/mL cytidine 5′-monophosphate (CMP, Sigma), or the combination of 
A771726 and UMP/CMP. RNA extraction was performed after 24 and 72 hrs after treatment.  
Crystal Violet Staining 
 10,000 cells were seeded per well in a 96 well plate in quadruplicate. Cells were fixed at 
different time point using 4% PFA (USB, Affymetrix) for 15 mins. Fixative was washed out with 1X 
PBS and cells were stained with 100 μL of 0.05% Crystal Violet  (Sigma) in 20% ethanol for 15 
mins. Crystal Violet was collected and plates were rinsed 3 times by immerging plates in a basin 
full of dH2O. Once plates were dried cells were dissolved by adding 100 mL of 1% SDS (in H2O). 
Absorbance was read at 540 nm by using a plate reader (SpectraMax M5, Molecular Devices)
Cell Line Nuclear Protein Extraction
 Nuclear protein was extracted from the A375 cells using the NE-PER Nuclear and 
Cytoplasm Extraction Kit (Thermo Scientific) following the prescribed protocol. 
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Concluding Discussion
DHODH Inhibition Suppresses Melanoma Through HEXIM1
 Leflunomide can act as an efficient anti-melanoma drug, both on its own and in synergy 
with vemurafenib (White et al., 2011). A combination therapy of these two drugs is currently in a 
clinical trial for metastatic melanoma. Leflunomide is a DHODH inhibitor that affects pyrimidine 
biosynthesis, resulting in the induction of a transcriptional pause. A significant pause is induced 
in genes involved in cell proliferation and cell cycle, thereby slowing the growth and proliferation 
of the neural crest and melanoma. However, the mechanism of how a shortage of nucleotides 
through DHODH inhibition can eventually lead to a transcriptional pause is unclear.
 Our work presented here demonstrates an important role for HEXIM1 in regulating this 
pause in transcription in melanoma in response to DHODH inhibition (Figure 4.1). We show that 
HEXIM1, as part of the 7SK snRNP, is bound to the promoter regions of genes (Figure 4.1A). This 
possibly poises P-TEFb at the promoters to allow rapid induction of transcription elongation when 
required. Leflunomide treatment induces a transient release of P-TEFb from the 7SK snRNP, 
releasing the transcriptional pause at a number of genes including HEXIM1 (Figure 4.1B). This 
results in an upregulation of HEXIM1 to sequester P-TEFb away from chromatin, thus preventing 
P-TEFb from phosphorylating RNA Pol II and other pausing factor (Figure 4.1C). Hence, RNA Pol 
II can no longer efficiently transition from a paused state into a productive elongation state. As 
a result, a large number of cell cycle and proliferative genes are downregulated and this in turn 
suppresses melanoma in vivo. Transcription elongation is an important step for highly regulated 
genes in development, as reviewed by Levine (Levine, 2011). Having RNA Pol II recruited to 
promoters prior to expression allows for rapid and concerted gene expression, which is crucial 
for proper gene expression at the appropriate developmental stage as well as during a stress 
response.
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 The significance of elongation in development might explain why HEXIM1 is downregulated 
in human melanoma. Tumorigenesis is often characterized by dedifferentiation and melanoma has 
been shown to express neural crest stem cell marker SOX10, which is typically not expressed in 
differentiated melanocytes (Shakhova, 2014; Shakhova et al., 2012). In addition, HEXIM1 and the 
7SK snRNP have been shown to regulate differentiation, possibly by controlling gene expression 
at the appropriate developmental stages to determine the cellular decision between proliferation 
and differentiation (Zhou and Yik, 2006). The fact that melanoma reverts to a dedifferentiated, 
proliferative state might therefore require HEXIM1 to be downregulated to maintain this tumorigenic 
state. We affirm the role of HEXIM1 in suppressing melanoma in our zebrafish melanoma model 
where even without induction by leflunomide, overexpressing human HEXIM1 can effectively 
suppress melanoma in vivo.
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Figure 4.1 A Model for DHODH Induced Melanoma Suppression by Upregulation of HEXIM1
(A) The 7SK snRNP poises P-TEFb at promoters such as the HEXIM1 promoter in preparation 
for transcription elongation at the appropriate time. (B) DHODH inhibition triggers P-TEFb 
release from the 7SK snRNP at a number of loci, including at HEXIM1. The free P-TEFb results 
in a transient release of pausing at the HEXIM1 gene, upregulating HEXIM1 transcription. (C) 
Newly synthesized HEXIM1 sequesters P-TEFb back into the 7SK snRNP away from chromatin, 
inhibiting transcription elongation at cell cycle and melanoma genes.
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 Upregulating HEXIM1 might prove to be a practical way of targeting melanoma. 
We discovered that leflunomide is a novel inducer of HEXIM1 expression other than JQ1 
(Bartholomeeusen et al., 2012b) and bipolar compounds such as HMBA (Zhong et al., 2014). 
Leflunomide targets a stress-related aspect of melanoma, where a shortage of pyrimidine 
nucleotides triggers a proliferation defect. The neural crest lineage seems to be particularly 
sensitive to nucleotide starvation, possibly due to an inactive nucleotide salvage pathway. As a 
result, leflunomide-induced HEXIM1 induction in the early, undifferentiated neural crest in zebrafish 
embryos causes an artificial growth-suppressive transcriptional response before the later stages 
of differentiation. This ablates the neural crest and its downstream lineages. Such an effect is 
mirrored in leflunomide treatment of melanoma since melanoma possesses characteristics of the 
undifferentiated neural crest. Hence, treating patients with leflunomide might induce HEXIM1 in 
many cell types, but the induction might have a more profound effect in melanoma because of its 
sensitivity to nucleotide starvation. The anti-proliferative effect of leflunomide will specifically be 
felt in melanoma more than in healthy tissues. This suggests that HEXIM1 is a major component 
of the anti-proliferative response caused by leflunomide. 
 Our work here demonstrates a novel mechanism to target melanoma other than existing 
targeted therapies that modulate the MAPK pathway. BRAF and MEK inhibitors currently improve 
the standard of care for melanoma patients, but the rapid evolution of resistance mechanisms 
to these drugs means that their effect is short-lived. Exploiting a more general pathway such as 
cellular stress to repress melanoma might be preferential since cancer cells will need to spend 
more resources to overcome the stress response. In the case of leflunomide, a drug-induced 
nucleotide shortage results in the inhibition of productive elongation by HEXIM1 at numerous 
proliferation and cell cycle genes. It might prove difficult for the melanomas to develop resistance 
mechanisms to overcome the transcriptional pause, as many components of the elongation 
mechanism such as HEXIM1 are essential for survival. Although the cancer might be able to 
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mutate DHODH so that leflunomide can no longer bind, mutating a gene involved in an essential 
cellular process might prove deleterious. More has to be done in characterizing other melanoma 
dependencies that can be targeted by drugs to modulate the proliferation and survival program in 
melanoma.
Inducers of HEXIM1 as Cancer Therapeutics
 There are currently four classes of compounds that induce HEXIM1 and have been 
investigated as possible cancer therapies. They are the bipolar compounds such as hexamethylene 
bisacetamide (HMBA) and dimethyl sulfoxide (DMSO) with unknown targets (Contreras et al., 
2007; Marks and Rifkind, 1989; Zhong et al., 2014), histone deacetylase (HDAC) inhibitors like 
suberoylanilide hydroxamic acid (SAHA) (Liu et al., 2014b; Richon et al., 1998), bromodomain and 
extra-terminal (BET) bromodomain inhibitor JQ1 (Bartholomeeusen et al., 2012b; Filippakopoulos 
et al., 2010; Liu et al., 2014b) and DHODH inhibitor leflunomide (based on our current study). 
These compounds have different targets but what is interesting is why they converge on the 
induction of HEXIM1 and modulation of the 7SK snRNP.
 HMBA and other bipolars compounds tested showed the distinct ability to induce terminal 
differentiation in a variety of cancer cell lines as reviewed by Marks and Rifkind (Marks and 
Rifkind, 1989). While the mechanism of how HMBA induces these changes is not well understood, 
studies in mouse erythroleukemia (MEL) cells demonstrated that HMBA caused multiple cellular 
changes, including transient cyclic AMP induction (Gazitt et al., 1978), protein kinase C activation 
(Melloni et al., 1987) and alteration of gene expression of c-myb, c-myc, c-fos and p53 (Lachman 
and Skoultchi, 1984; Ramsay et al., 1986; Todokoro and Ikawa, 1986). All of which resulted in 
the consequent expression of differentiation markers such as globins and heme biosynthesis 
enzymes, as well as changes in morphology of the MEL cells. These studies provide evidence 
that HMBA and other bipolar compounds either target multiple factors in different pathways or 
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one factor that affects multiple downstream pathways. However, the direct targets of bipolar 
compounds remain elusive. HMBA had previously been tested in a clinical trial for myelo-dysplastic 
syndrome and acute myelogenous leukemia (Andreeff et al., 1992). Although the drug induced 
remission in patients, it is not currently utilized in the clinic because of the high dose needed and 
toxic side effects such as thrombocytopenia (Andreeff et al., 1992). There are currently efforts to 
design more potent HMBA analogues with longer half-lives for disease treatment (Zhong et al., 
2014). More has to be done to identify the targets of HMBA to develop more potent drugs to these 
targets.
 HDAC inhibitors like SAHA were synthesized as the second generation of bipolar 
compounds (newly termed “hybrid polar compounds” based on chemical modifications) and were 
designed based on HMBA to achieve more potent induction of cellular differentiation (Richon et 
al., 1996). They are up to 2000-fold more active than HMBA in inducing differentiation in MEL cells 
(Richon et al., 1996). These hybrid polar compounds were thought to target the same pathways 
as HMBA, and might therefore lead to the discovery of what HMBA targets in cells. Fortunately 
for hybrid polar compounds, they where found to specifically inhibit HDACs, resulting in hyper-
acetylation of histones which induced gene expression changes responsible for the differentiation 
phenotype (Richon et al., 1998). Unfortunately for HMBA, it was not found to target HDACs like 
hybrid polar compounds (Richon et al., 1998), so its targets still remain a mystery. The ability 
of HDAC inhibitors to induce cellular differentiation and apoptosis has been particularly useful 
in treating cancer, as reviewed by Wagner et. al. (Wagner et al., 2010). A number of HDAC 
inhibitors have been or are currently being tested in clinical trials for a wide array of cancers, 
with compounds Vorinostat and Romedepsin having already been FDA approved for treatment of 
refractory T-cell lymphoma (Wagner et al., 2010). Not much has been investigated in terms of how 
HEXIM1 induction by HDAC inhibition is responsible for the anti-tumorigenic effect, and further 
study could prove useful in understanding the complex cellular changes that occur to induce 
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differentiation or apoptosis in cancer.
 BET domain inhibition is a more recent published discovery of a novel way to target 
cancer. A study in multiple myeloma found that the BET domain-containing gene BRD4 locus was 
frequently amplified in patients with this disease (Delmore et al., 2011). BET domain inhibitor JQ1 
was developed to target BRD4 (Filippakopoulos et al., 2010), and this drug results in a pronounced 
anti-proliferative effect in multiple myeloma (Delmore et al., 2011). BRD4 was shown to be a 
transcriptional activator of oncogenic MYC expression (Delmore et al., 2011). Thus, inhibition 
of BRD4 by JQ1 suppresses MYC, resulting in an anti-proliferative state that suppresses the 
cancer. Interestingly, gene expression data from JQ1 inhibition in multiple myeloma revealed 
that HEXIM1 is significantly upregulated (Delmore et al., 2011). Biochemical analysis of JQ1 in 
Jurkat cells revealed that BET domain inhibition caused identical effects on the 7SK snRNP as 
with SAHA and HMBA (Bartholomeeusen et al., 2012b). JQ1 treatment causes an initial release 
of P-TEFb from the 7SK snRNP followed by increased HEXIM1 expression and subsequent re-
sequestration of P-TEFb by newly synthesized HEXIM1 (Bartholomeeusen et al., 2012b). These 
three drugs that represent different classes cause an initial transient release of P-TEFb from the 
7SK snRNP, followed by HEXIM1 upregulation and subsequent reassembly of the 7SK snRNP 
(Bartholomeeusen et al., 2012b).
 We have identified a novel pathway that induces HEXIM1 and modulates the 7SK snRNP 
through DHODH inhibition by leflunomide. Leflunomide employs a transient release of P-TEFb 
from the 7SK snRNP and subsequent HEXIM1 induction similar to the aforementioned mechanism 
of bipolar compounds, HDAC inhibitors and BET domain inhibitor JQ1. We demonstrate that 
HEXIM1 and the 7SK snRNP are necessary for the anti-melanoma effect of leflunomide, and that 
HEXIM1 itself can functionally suppress tumorigenesis. Leflunomide seems to induce HEXIM1 
in a different manner from the other three compound classes, as it creates a state of nucleotide 
starvation in the cell. This stress state is what drives the cell to induce HEXIM1 to suppress its 
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proliferation and cell cycle program, and induction of this stress by leflunomide can be exploited 
to treat cancer. It is evident that there are a number of pathways that can induce HEXIM1 and 
modulate the 7SK snRNP. Further comprehension of these pathways could result in novel 
combination therapies to induce HEXIM1 through modulation of these convergent pathways to 
achieve highly potent tumor suppression.
HEXIM1 Responds to Nucleotide Stress
 Other than its ability to suppress melanoma, HEXIM1 also plays an important role in 
nucleotide metabolism. DHODH inhibition by leflunomide creates a state of cellular stress caused 
by pyrimidine nucleotide starvation. We demonstrate that HEXIM1 expression is responsive 
to perturbations in pyrimidine nucleotide levels. This fits with a model where the cell senses 
low nucleotides and upregulates HEXIM1. This upregulation inhibits productive elongation on a 
large number of genes, giving the cell an opportunity to either synthesize nucleotides de novo 
or salvage them from other metabolites before transcription can return to homeostatic levels. 
Hence, HEXIM1 provides an elegant mechanism where nucleotide biosynthesis is linked with 
transcription elongation so that there are always sufficient pools of mRNA precursors.
 Linking nucleotide regulation with transcription elongation also has a number of benefits. 
Halting productive elongation temporarily means that RNA Pol II remains bound to the promoter 
regions of genes, albeit in a paused state. This allows for a rapid return to homeostatic gene 
expression once nucleotide levels returns to normal, since RNA Pol II remains poised for 
transcription without the initiation step being required again. Initiation first requires the formation 
of euchromatin by chromatin factors, followed by stochastic binding of RNA Pol II recruitment 
factors that brings RNA Pol II to the promoters. After which, pausing factors are recruited to the 
promoters to hold RNA Pol II in position to await Cdk9 phosphorylation, which ultimately triggers 
the transition from a paused state to productive elongation. This chain of events takes time and 
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would not benefit the cell if the cycle has to be repeated every time nucleotide levels return to 
normal after starvation. It seems more efficient to regulate transcription by increased HEXIM1 
sequestration of P-TEFb, thus inhibiting productive elongation at a stage in transcription that can 
rapidly return to normalcy once the stress is alleviated.
 The HEXIM1 gene falls into a category of genes that are not paused by leflunomide. It 
is interesting that nucleotide starvation induced by leflunomide does not cause a transcriptional 
pause in all genes. The pause is preferential for cell cycle and proliferative genes while genes 
such as HEXIM1 that maintain the paused state are unaffected or upregulated. There might exist 
a mechanism where nucleotide starvation causes cells to preferentially upregulate genes that 
will conserve nucleotide precursors, salvage them or synthesize them. HEXIM1 seems to be 
responsible for the conservation of nucleotides by inhibiting the transition from a paused state 
to productive elongation. It would be interesting to investigate the mechanism behind these 
differences in gene expression due to nucleotide stress.
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Future Directions
Introduction
 From our work thus far, we have uncovered how leflunomide acts through HEXIM1 in 
order to inhibit productive elongation to suppress melanoma. We also demonstrate that HEXIM1 
suppresses tumorigenesis and is downregulated in melanoma for the tumors to proliferate. There 
remain a number of questions about this mechanism. Although leflunomide prevents the transition 
from a paused state to a productive elongation state at many genes, there are still a number of 
genes like HEXIM1 that are induced to elongate. This observation hints at a complex mechanism 
upstream of HEXIM1 induction and downstream of nucleotide biosynthesis that has yet to be 
identified. Some clues of how a shortage of nucleotides can directly influence transcription can 
be found in yeast. Ppr1p is a DNA binding yeast protein that can induce the transcription of the 
URA pyrimidine biosynthesis genes upon the addition of pyrimidine precursors dihydroorotate 
or orotate (Flynn and Reece, 1999). This posits an interesting mechanism where a build up of 
pyrimidine precursors (dihydroorotate and/or orotate) activates a transcription factor (Ppr1p) 
possibly by binding to it, resulting in an upregulation of downstream pyrimidine biosynthesis genes 
(URA genes) by the activated transcription factor. Since leflunomide causes an upregulation of 
pyrimidine precursors upstream of DHODH, these precursors might potentially bind to activate or 
deactivate proteins that have a direct impact on transcription.
 Our next step would be to uncover the factors upstream of HEXIM1-mediated inhibition of 
elongation in response to low nucleotide levels. One can envision cellular mechanisms that regulate 
either HEXIM1 expression or HEXIM1 functioning in the 7SK snRNP. We have determined that 
leflunomide upregulates HEXIM1 mRNA and protein levels in mammalian melanoma cells and in 
zebrafish. To examine how alterations in HEXIM1 expression are achieved by leflunomide, we will 
first generate a list of candidate transcription factors that have been shown to bind the HEXIM1 
locus from current literature. We can then knock down these factors via small-interfering RNA 
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(siRNA) technology in a mini-screen to determine which transcription factor(s) is/are responsible 
for HEXIM1 induction by leflunomide. Once we have positive hits, we can perform downstream 
assays to see if they respond to nucleotide starvation or other cellular stresses to induce HEXIM1 
expression. Discovering the transcription factors involved in regulating HEXIM1 expression in 
nucleotide stress conditions will help piece together a feedback mechanism where nucleotide 
levels directly control and regulate transcription.
 In addition to transcriptional regulation of HEXIM1, leflunomide probably induces 
biochemical changes in the 7SK snRNP that causes the initial release and subsequent re-
sequestration of P-TEFb we have shown. HEXIM1 is phosphorylated at a number of potential 
sites in order to regulate P-TEFb binding (Contreras et al., 2007; Fujinaga et al., 2012). Hence, 
we will perform phosphorylation site mapping of HEXIM1 via mass spectrometry to determine if 
leflunomide causes changes in the phosphorylation state of HEXIM1 and which phosphorylation 
sites specifically are affected. We can then examine the sites modified for amino acid motifs 
recognized by kinases and phosphatases to shortlist candidate enzymes that potentially modify 
HEXIM1 at these sites. We can complement this study with a phosphorylated protein array on 
leflunomide-treated A375 cells, where we can examine changes in phosphorylation state of a wide 
variety of signal transduction proteins due to drug. These experiments will allow us to compare 
hits and shortlist potential kinases and phosphatases that modify HEXIM1 in response to DHODH 
inhibition. Once we determine which site(s) on HEXIM1 is/are modified by which enzyme, we can 
then proceed to validate our results in downstream cell-based or zebrafish assays. Determining 
how HEXIM1 is biochemically modified will identify upstream signal transduction pathways that 
feed into the downstream regulation of transcription during nucleotide deficiency.
 Other than direct biochemical modification of HEXIM1, a third avenue we will pursue is the 
discovery of factors that physically modify the 7SK snRNP or recruit it to target genes in response 
to DHODH inhibition. Firstly, there is evidence for factors such as PP2B and PP1α that induce a 
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conformational change in the 7SK snRNP to disrupt the complex (Chen et al., 2008). Secondly, it 
is possible that factors exist to selectively recruit the 7SK snRNP to chromatin in order to inhibit 
transcription at specific loci. Thirdly, there is evidence that HEXIM1 can bind RNA species other 
than the 7SK RNA (Fujimoto et al., 2012). To address if leflunomide treatment elicits protein factors 
to modify the function of the 7SK snRNP, we will co-immunoprecipitate HEXIM1 with its binding 
partners to identify these partners by mass spectrometry. By comparing mass spectrometry results 
in DMSO- and leflunomide-treated cells, we can ascertain changes in binding partners caused 
by the drug. Candidate proteins that modulate the function of the 7SK snRNP can be tested in 
biochemical and genetic assays to validate their relevance to leflunomide-induced changes in 
the 7SK snRNP. To address novel RNA species that might bind and affect HEXIM1 function, we 
will perform high-throughput sequencing of RNA isolated by cross-linking immunoprecipitation 
(HTS-CLIP) (Licatalosi et al., 2008) to identify strong RNA binders of HEXIM1. After which, we 
will validate the ability of candidate RNAs to activate HEXIM1 in downstream assays. Identifying 
factors that modulate the 7SK snRNP with DHODH inhibition will further develop our understanding 
of transcriptional regulation in response to cellular stress.
 Finally, we hope to discover novel therapeutics that can exploit stress pathways that induce 
HEXIM1 to target melanoma and other cancers. We demonstrate that HEXIM1 can robustly 
suppress melanoma. In addition, previous studies have implicated the importance of HEXIM1 
and LARP7 in a variety of other cancers (Cheng et al., 2012b; He et al., 2008; Ketchart et al., 
2013; Mascareno et al., 2012; Mori et al., 2002; Wittmann et al., 2003, 2005; Yeh et al., 2013). 
Thus far, bipolar compounds such as HMBA, HDAC inhibitor SAHA, BRD4 inhibitor JQ1 and 
our DHODH inhibitor leflunomide have been shown to induce HEXIM1 to target tumorigenesis. 
However, the detailed mechanism of how these drugs activate HEXIM1 is not well understood. To 
address this question, we intend to conduct a chemical screen on the A375 HEXIM1-Luciferase 
reporter cell line. This will allow us to obtain hit compounds of drugs with either known or unknown 
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mechanisms-of-action. With the list of drugs with known targets, we can discern potential pathways 
that upregulate HEXIM1 and test them in future assays. As an additional benefit, all hits obtained 
are potential cancer therapeutics that function through the 7SK snRNP and should be validated for 
anti-tumor activity. A screen for chemical modulators of HEXIM1 expression will aid the discovery 
of novel cancer therapeutics and refinement of the upstream mechanisms that govern HEXIM1 
expression and function.
Transcription Factor Screen on HEXIM1
 We demonstrate that DHODH inhibition causes a transient release of P-TEFb from the 
7SK snRNP, which causes an upregulation of HEXIM1. There might be other factors that mediate 
HEXIM1 upregulation other than a transient release of P-TEFb alone. Hence, we examined the 
ENCODE database of ChIP-seq experiments performed with different transcription factors on a 
variety of cell lines within the UCSC Genome Browser. From this, we created a list of candidate 
transcription factors that seemingly bind the HEXIM1 promoter under various contexts. With this 
list, we intend to perform a transcription factor siRNA screen to determine which factor(s) is (are) 
responsible for HEXIM1 upregulation by leflunomide. The candidates we will test are CTCF, 
EGR1, ELF1, HEY1, cMYC, SP1, USF1 and YY1 and the controls are scrambled siRNA, HEXIM1 
and GAPDH. A375 cells treated with DMSO or A771726 will be subjected to siRNA knockdown 
for each of the factors listed. RNA will be isolated for real time RT-PCR for ACTB, GAPDH and 
HEXIM1 and protein will be isolated for western blotting of ACTB and HEXIM1.
 We hypothesize that this screen will discover potential activators or repressors of HEXIM1. 
Knockdown of one or more of these factors will either block HEXIM1 upregulation by A771726 
(activators) or unblock HEXIM1 upregulation in the DMSO control (repressors). DHODH inhibitors 
can therefore upregulate HEXIM1 expression either by increasing recruitment of transcriptional 
activators or reducing the occupancy of transcriptional repressors at the HEXIM1 locus. We can 
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validate how these factors respond to DHODH inhibition by performing ChIP-PCR using the 
HEXIM1 promoter region as readout for binding. In addition, we can mutate the predicted binding 
motifs of the shortlisted factors on the HEXIM1 promoter and determine if this has any effect on 
the ability of leflunomide to induce HEXIM1 transcription.
Mass Spectrometry Analysis on the 7SK snRNP
 We have shown that HEXIM1 is transcriptionally induced by DHODH inhibition to 
achieve inhibition of productive elongation. However, there is a biochemical level of 7SK snRNP 
regulation that we have yet to examine. The 7SK snRNP has been shown to be phosphorylated, 
dephosphorylated and structurally modified at a number of sites that modulate its ability to 
sequester and inhibit P-TEFb (Chen et al., 2008; Cho et al., 2009; Contreras et al., 2007; Fujinaga 
et al., 2012). We would like to establish the homeostatic HEXIM1 phosphorylation state in human 
melanoma by performing protein mass spectrometry on HEXIM1 protein that is immunoprecipitated 
from the A375 cell lines. This method will allow us to validate the literature in terms of which sites 
are phosphorylated in vivo. Furthermore, we can perform mass spectrometry on cells treated with 
DMSO and A771726 to determine if the drug causes any changes in the phosphorylation state of 
HEXIM1.
 In addition to phosphorylation state, protein mass spectrometry can also give us an 
additional readout of HEXIM1 binding partners. There is evidence that other factors can bind 
HEXIM1, such as the glucocorticoid receptor (Shimizu et al., 2005), and it would be insightful to 
examine if leflunomide causes any changes in the association of factors with the 7SK snRNP. 
These factors could potentially affect 7SK snRNP nucleation or localization in the nucleus in 
response to DHODH inhibition. We hypothesize that one or more phosphorylation events on 
HEXIM1 will be changed in response to leflunomide and that we will find binding partners that 
are either responsible for localizing the 7SK snRNP to chromatin (transcription factors) or for 
91
modifying its phosphorylation state (kinases and phosphatases).
Protein Phosphorylation Array on A771726-Treated A375 Cells
 We have subjected DMSO and A771726-treated A375 cells to a human protein 
phosphorylation array to determine which signal transduction pathways are modified in terms 
of phosphorylation state in response to drug (Figure 4.2A). By visual inspection, focal adhesion 
kinase (FAK) and STAT6 phosphorylation are downregulated by A771726. FAK is a cytoplasmic 
tyrosine kinase that is co-activated by integrin and VEGFR-2 receptors to control vascular 
permeability, and seems to be responsible for tumor metastasis (Chen et al., 2012). Its expression 
and activation is elevated in malignant astrocytomas and ovarian cancer (Halder et al., 2007; 
Haskell et al., 2003). In addition, its inhibition or knockdown has been shown to suppress non-
small cell lung cancer and ovarian cancer (Halder et al., 2007; Li et al., 2013a). STAT6 is a member 
of the JAK-STAT pathway which is activated in a number of cancers, such as breast, ovarian and 
prostate cancer, as reviewed by Furqan et. al. (Furqan et al., 2013). STAT inhibitors are currently 
being developed and tested for tumor suppression activity (Furqan et al., 2013). In addition to FAK 
and STAT6 downregulation of phosphorylation, tumor suppressor p53 is significantly upregulated 
at three different phosphorylation sites by A771726. 
 Further analysis of the blots was performed in ImageJ and this confirmed more candidate 
proteins that are significantly altered by drug (Figure 4.2B). Based on the cut-off of > 1.5 fold 
up- or downregulation of phosphorylation and a p-value of < 0.05, we further shortlisted proteins 
that we considered significantly altered (Figure 4.2C). Interestingly, only p53 phosphorylation is 
significantly upregulated and on all three sites probed (Figures 4.3A and 4.3C). We also shortlisted 
FAK and STAT6 phosphorylation as being downregulated, which we previously observed by eye. 
Other interesting proteins which experience a downregulation of phosphorylation by DHODH 
inhibition include c-Jun N-terminal kinases (JNKs) and platelet-derived growth factor (PDGF), 
92
both of which are implicated in cancer (Alvarez et al., 2006; Song et al., 2014). A771726 seems 
to inhibit a number of tumor oncogenes and activate tumor suppressor p53 to achieve its tumor-
suppressive function. 
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A DMSO A771726 - 60 µM
*P < 0.05
Figure 4.2. Signal transduction pathways affected by DHODH inhibition
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Figure 4.2 Signal Transduction Pathways Affected by DHODH Inhibition
(A) Lysates from A375 cells treated with DMSO or 60 μM A771726 for 72 hrs were applied to a 
human phospho kinase antibody array. (B) ImageJ was used to determine the relative changes in 
pixel density for each antibody signal in the DMSO condition compared to A771726. (C) Significantly 
altered protein phosphorylation events are tabulated based on a relative fold change in pixel 
density of > 1.5-fold increase or decrease, and a Student’s two-tailed t-test p-value cut-off of < 0.05.
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 Now that we have obtained candidates for signal transduction pathways that either directly 
or indirectly affect the 7SK snRNP, the next step is to test the appropriate kinase inhibitors or 
protein knockdowns to determine which ones are responsible for the changes to the 7SK snRNP 
caused by leflunomide. There are a number of proteins on the array that are expressed at a low 
levels, so it might be worth purchasing antibodies to determine if the phosphorylation state of these 
proteins is affected by DHODH inhibition as well. Once we have validated which pathways are 
responsible for the changes in 7SK snRNP phosphorylation, we can develop a clearer upstream 
mechanistic network of how transcription elongation is affected by various signals.
Investigation of Alternative RNA Binders to HEXIM1
 There is evidence that HEXIM1 can bind RNA species other than the 7SK RNA (Fujimoto 
et al., 2012). One mRNA candidate that potentially binds to HEXIM1 is the CAD gene, which 
expresses the gate-keeper enzyme of pyrimidine biosynthesis (Jones, 1980). Since DHODH 
inhibition blocks pyrimidine biosynthesis, there might be some relevance to HEXIM1 regulation 
by CAD mRNA in order to regulate transcription. We previously showed that N-carbamoyl-L-
aspartate is the earliest metabolite to be significantly upregulated with DHODH inhibition in the 
A375 cells, and this metabolite is an intermediate synthesized by CAD. In addition, cad mRNA 
expression is increased in zebrafish treated with leflunomide at a similar level to hexim mRNA, while 
melanocyte markers mitfa and dct are downregulated (White et al., 2011) as previously published 
(Figure 4.3). To investigate the possible relationship between CAD mRNA and HEXIM1 function, 
we will perform high-throughput sequencing of RNA isolated by cross-linking immunoprecipitation 
(HTS-CLIP) (Licatalosi et al., 2008) on A375 cells treated with DMSO or A771726 to determine if 
HEXIM1 indeed binds CAD mRNA and if there is any alteration of binding with drug.
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 We hypothesize that CAD mRNA will be induced to bind HEXIM1 in a state of nucleotide 
starvation caused by leflunomide (Figure 4.4). This will activate HEXIM1 regardless of 7SK 
RNA binding to inhibit productive elongation, thus halting cell proliferation and the cell cycle 
until nucleotide levels return to normal. From HTS-CLIP, we can also discover potential novel 
interactions that act like CAD mRNA to regulate transcription in nucleotide level sensing.
Figure 4.3 DHODH Inhibition Upregulates cad mRNA
Real time RT-PCR was performed on zebrafish embryos treated with leflunomide from 50% 
epiboly to 24 hpf. Genes examined were mitfa, dct, hexim and cad. Data is normalized to gapdh.
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Figure 4.4 A Model for DHODH Induced CAD mRNA Expression to Inhibit Elongation via 
HEXIM1
(A) The 7SK snRNP poises P-TEFb at the CAD promoter in preparation for transcription elongation 
at the appropriate time. (B) DHODH inhibition triggers P-TEFb release from the 7SK snRNP at 
the CAD locus. The free P-TEFb results in a transient release of pausing at the CAD gene, 
upregulating CAD transcription. (C) Newly synthesized CAD mRNA binds HEXIM1, activating it 
to sequester P-TEF and consequently inhibiting transcription elongation at proliferation and cell 
cycle genes.
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Chemical Screen for Novel Inducers of HEXIM1
 There are already a number of drugs that are known to upregulate HEXIM1, including 
leflunomide that we show here. Since HEXIM1 has demonstrated strong tumor suppressing 
potential in a number of cancers, it might be prudent to discover more pathways that can modulate 
HEXIM1 expression to target melanoma. We can perform a high-throughput chemical screen 
on our HEXIM1-Luciferase reporter A375 line to rapidly detect compounds that significantly 
upregulate HEXIM1 expression. This screen will generate chemical probes to further comprehend 
HEXIM1 biology as well as potential targeted therapies for melanoma and other cancers. Since 
this is a cell-based screen, we can easily plate cells into 48- or 96-well format and deliver chemical 
libraries to these cells via robot. The luciferase reporter system will allow automated collection 
of plate images after the addition of fluorescent substrate. In addition, we can design algorithms 
to quantify fluorescence intensities in the images to further expedite the determination of hit 
compounds. Performing a secondary luciferase assay with a dose-response curve will validate 
chemical hits. After hits are verified, we will assign them to categories either through a literature 
search or with online tools such as Discovery Gate (Accelrys). Further cell culture, biochemical 
and zebrafish assays will be performed on hits-of-interest to discover their basis of HEXIM1 
induction.
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Materials and Methods
Human Phospho-kinase Array
 We treated A375 cells with DMSO or 60 μM A771726 for 72 hrs and obtained lysates as 
recommended by the manufacturer’s protocol in the protein array (RnD Systems). We normalized 
total protein levels in the supernatants using the DC Protein Assay (Bio-rad). We then applied 
the lysates to the proteome profiler human phospho-kinase array ARY003B (RnD Systems) 
and imaged the blots with a traditional western film developer. Pixel densitometry analysis was 
performed in ImageJ (NIH).
RNA Extraction and Quantitative RT-PCR Analysis
 RNA isolation was performed using TRIzol (Life Technologies), and subsequently treated 
with the TURBO DNA-free kit (Life Technologies). cDNA was synthesized with the SuperScript III 
Kit (Life Technologies).  Quantitative PCR was performed on the iQ5 real-time PCR machine using 
the Ssofast EvaGreen Supermix (BioRad). The ∆∆Ct method was used for relative quantification. 
RT-PCR primers are:
hexim forward: 5’-CAAACACGAGATTTGAGTTAAACG-3’
hexim reverse: 5’-CTCGTCCGATAATCTCTCTGC-3’
cad forward: 5’-ATGGAGGAAATCAACGAGCA-3’
cad reverse: 5’-GACCAGAACCGGATAACCAA-3’
mitfa forward: 5’-GGCGGTTTAATATCAATGACAGA-3’
mitfa reverse: 5’-GGTGCCTTTATTCCACCTCA-3’
dct forward: 5’-CACCTGGCACAGATATCACCT-3’
dct reverse: 5’-CGGCGAAGTTCTCATTACCT-3’
gapdh forward: 5’-GTGGAGTCTACTGGTGTCTTC-3’
gapdh reverse: 5’-GTGCAGGAGGCATTGCTTACA-3’
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